Derivatives of GLP-1 Like Peptides, and Uses Thereof

ABSTRACT

The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogues of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/322,077, filed Jul. 2, 2014 which claims priority under 35 U.S.C.§119 of U.S. Provisional Application 61/845,646, filed Jul. 12, 2013;this application further claims priority of European Application13175094.5, filed Jul. 4, 2013; the contents of all above-namedapplications are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to derivatives of GLP-1 like peptides,which may be defined as C-terminally extended analogues of glucagon-likepeptide 1 (GLP-1). The derivatives are double-acylated, and one of theacyl side chains is attached to the C-terminal amino acid of the GLP-1like peptide. The invention also relates to the pharmaceutical use ofthese derivatives.

INCORPORATION-BY-REFERENCE OF THE SEQUENCE LISTING

In accordance with 37 C.F.R. §1.52(e)(5), Applicants enclose herewiththe Sequence Listing for the above-captioned application entitled“8706US02_Sequence_ST25”, created on Sep. 19, 2016. The Sequence Listingis made up of 7.20 kilobytes, and the information contained in theattached “8706US02_Sequence_ST25” is identical to the information in thespecification as originally filed. No new matter is added.

BACKGROUND

WO 2009/030771 A1 and WO 2011/080102 disclose a number of mono-acylatedGLP-1 derivatives including some that are acylated with C12-C20 fattydiacids.

WO 2012/140117 A1, WO 2012/062803 A1 and WO 2012/062804 A1 disclose anumber of double-acylated GLP-1 derivatives including some that areacylated with C12-C18 fatty diacids.

SUMMARY

Liraglutide is a GLP-1 derivative for once daily administration. It ismarketed under the trade name of VICTOZA® by Novo Nordisk A/S.

Semaglutide is a GLP-1 derivative for once weekly administration. It isunder development by Novo Nordisk A/S. This compound is disclosed in WO2006/097537 Example 4.

The invention relates to derivatives of GLP-1 like peptides which havepotential for once monthly administration.

In one aspect the invention relates to derivatives of GLP-1 likepeptides, which are double-acylated. One of the acylation sites is atthe C-terminus, more in particular at the position which when comparedwith native GLP-1(7-37) would correspond to position number 42. Theother acylation site is internally in the GLP-1 like peptide, more inparticular at one of the positions corresponding to position 18, 23, 27,31, 36, or 38 in native GLP-1(7-37). A long fatty diacid is used forboth of the two acylations.

In a second aspect the invention relates to pharmaceutical compositionscomprising such derivatives and pharmaceutically acceptable excipients,as well as the medical use of the derivatives.

In a third aspect, the invention relates to intermediate products in theform of novel GLP-1 analogues, which can be incorporated in thederivatives of the invention. Such analogues may comprise the followingamino acid changes when compared to GLP-1 (7-37) (SEQ ID NO: 1): i)(8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii) (8Aib, 22E,26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E, 26R, 34R, 38K,39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S,42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K); vi) (8Aib,18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K); vii) (7Imp, 8Aib, 22E,26R, 34R, 38K, 39G, 40G, 41S, 42K); iix) (8Aib, 22E, 26R, 34R, 36K, 38A,39E, 40S, 41P, 42K); ix) (8Aib, 22E, 26R, 34R, 36K, 38E, 39G, 40P, 41A,42K); x) (8Aib, 22E, 26R, 34R, 36K, 38P, 39A, 40S, 41E, 42K); xi) (8Aib,22E, 26R, 34R, 38K, 39P, 40E, 41G, 42K) (SEQ ID NO: 12); xii) (8Aib,22E, 26R, 34R, 38K, 39S, 40A, 41E, 42K); or xiii) (8Aib, 22E, 26R, 34R,38K, 39S, 40P, 41E, 42K).

The amino acid sequence of native human GLP-1(7-37) is included in thesequence listing as SEQ ID NO: 1 and SEQ ID NO's 2-14 are specific GLP-1analogues of the GLP-1 derivatives of the invention.

The derivatives of the invention represent a remarkable leap in thesearch for GLP-1 derivatives of very long half-lives and still with avery good potency.

DESCRIPTION

In what follows, Greek letters may be represented by their symbol or thecorresponding written name, for example: α=alpha; β=beta; ε=epsilon;γ=gamma; δ=delta; ω=omega; etc. Also, the Greek letter of μ may berepresented by “u”, e.g. in μl=ul, or in μM=uM.

An asterisk (*) in a chemical formula designates i) a point ofattachment, ii) a radical, and/or iii) an unshared electron.

In its first aspect the invention relates to a derivative of a GLP-1like peptide, wherein the GLP-1 like peptide comprises a peptide offormula I:

Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,wherein

Xaa₇ is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid,D-histidine, desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine; Xaa₈ is Ala, Gly, Ser, Aib,(1-aminocyclopropyl) carboxylic acid, or (1-aminocyclobutyl) carboxylicacid; Xaa₁₂ is Phe or Leu; Xaa₁₆ is Val or Leu; Xaa₁₈ is Ser, Arg, Lys,Val, or Leu; Xaa₁₉ is Tyr or Gln; Xaa₂₀ is Leu or Met; Xaa₂₂ is Gly orGlu; Xaa₂₃ is Gln, Glu, Lys, or Arg; Xaa₂₅ is Ala or Val; Xaa₂₆ is Argor Lys; Xaa₂₇ is Glu, Lys, or Leu; Xaa₃₀ is Ala, Glu, or Arg; Xaa₃₁ isTrp, Lys, or His; Xaa₃₃ is Val, Lys, or Arg; Xaa₃₄ is Lys, Arg, His,Asn, or Gln; Xaa₃₅ is Gly or Ala; Xaa₃₆ is Arg, Lys, or Gly; Xaa₃₇ isGly or Pro; Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys; Xaa₃₉ is Ser, Gly,Ala, Glu, or Pro; Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₁ is Ser,Gly, Ala, Glu, or Pro; and Xaa₄₂ is Lys; with the proviso that at leastone of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys; wherein Lysat Xaa₄₂ is a first K residue, and a Lys at one of Xaa₁₈, Xaa₂₃, Xaa₂₇,Xaa₃₁, Xaa₃₆, or Xaa₃₈ is a second K residue; which derivative comprisesa first and a second protracting moiety connected to said first andsecond K residue, respectively, wherein the first and the secondprotracting moiety is of formula Chem. 1: HOOC—(CH₂)₁₈—CO—*, Chem. 1a:HOOC—(CH₂)₁₇—CO—*, or Chem. 1b: HOOC—(CH₂)₂₀—CO—*; or a pharmaceuticallyacceptable salt, amide, or ester thereof.

In its second aspect, the invention relates to a pharmaceuticalcomposition comprising a derivative of the invention and apharmaceutically acceptable excipient; and the use of the derivative oranalogue of the invention as a medicament, in particular for use in the(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C; (ii)delaying or preventing diabetic disease progression, such as progressionin type 2 diabetes, delaying the progression of impaired glucosetolerance (IGT) to insulin requiring type 2 diabetes, delaying orpreventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes; (iii) improving β-cell function, such as decreasing β-cellapoptosis, increasing β-cell function and/or β-cell mass, and/or forrestoring glucose sensitivity to β-cells; (iv) prevention and/ortreatment of cognitive disorders and/or neurodegenerative disorders,such as Alzheimer's disease, Parkinson's disease, and/or multiplesclerosis; (v) prevention and/or treatment of eating disorders, such asobesity, e.g. by decreasing food intake, reducing body weight,suppressing appetite, inducing satiety; treating or preventing bingeeating disorder, bulimia nervosa, and/or obesity induced byadministration of an antipsychotic or a steroid; reduction of gastricmotility; delaying gastric emptying; increasing physical mobility;and/or prevention and/or treatment of comorbidities to obesity, such asosteoarthritis and/or urine incontinence; (vi) prevention and/ortreatment of diabetic complications, such as angiopathy; neuropathy,including peripheral neuropathy; nephropathy; and/or retinopathy; (vii)improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo; (viii) prevention and/or treatment of cardiovascular diseases,such as syndrome X, atherosclerosis, myocardial infarction, coronaryheart disease, reperfusion injury, stroke, cerebral ischemia, an earlycardiac or early cardiovascular disease, left ventricular hypertrophy,coronary artery disease, hypertension, essential hypertension, acutehypertensive emergency, cardiomyopathy, heart insufficiency, exerciseintolerance, acute and/or chronic heart failure, arrhythmia, cardiacdysrhythmia, syncope, angina pectoris, cardiac bypass and/or stentreocclusion, intermittent claudication (atherosclerosis oblitterens),diastolic dysfunction, and/or systolic dysfunction; and/or reduction ofblood pressure, such as reduction of systolic blood pressure; (ix)prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus; (x) prevention and/or treatment of criticalillness, such as treatment of a critically ill patient, a criticalillness poly-nephropathy (CIPNP) patient, and/or a potential CIPNPpatient; prevention of development of critical illness or CIPNP;prevention, treatment and/or cure of systemic inflammatory responsesyndrome (SIRS) in a patient; prevention or reduction of the likelihoodof a patient suffering from bacteremia, septicemia, and/or septic shockduring hospitalization; and/or stabilising blood glucose, insulinbalance and optionally metabolism in intensive care unit patients withacute illness; (xi) prevention and/or treatment of polycystic ovarysyndrome (PCOS); (xii) prevention and/or treatment of cerebral disease,such as cerebral ischemia, cerebral haemorrhage, and/or traumatic braininjury; (xiii) prevention and/or treatment of sleep apnea; and/or (xiv)prevention and/or treatment of abuse, such as alcohol abuse and/or drugabuse.

In its third aspect, the invention relates to an intermediate product inthe form of a GLP-1 analogue, which comprises the following amino acidchanges when compared to GLP-1 (7-37) (SEQ ID NO: 1):

i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii) (8Aib, 22E,26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E, 26R, 34R, 38K,39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S,42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K); vi) (8Aib,18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K); vii) (7Imp, 8Aib, 22E,26R, 34R, 38K, 39G, 40G, 41S, 42K); iix) (8Aib, 22E, 26R, 34R, 36K, 38A,39E, 40S, 41P, 42K); ix) (8Aib, 22E, 26R, 34R, 36K, 38E, 39G, 40P, 41A,42K); x) (8Aib, 22E, 26R, 34R, 36K, 38P, 39A, 40S, 41E, 42K); xi) (8Aib,22E, 26R, 34R, 38K, 39P, 40E, 41G, 42K) (SEQ ID NO: 12); xii) (8Aib,22E, 26R, 34R, 38K, 39S, 40A, 41E, 42K); or xiii) (8Aib, 22E, 26R, 34R,38K, 39S, 40P, 41E, 42K); or which is selected from these analogues.

GLP-1 Receptor Agonist

A receptor agonist may be defined as an analogue that binds to areceptor and elicits a response typical of the natural ligand. A fullagonist may be defined as one that elicits a response of the samemagnitude as the natural ligand (see e.g. “Principles of Biochemistry”,A L Lehninger, D L Nelson, M M Cox, Second Edition, Worth Publishers,1993, page 763).

Thus, for example, a “GLP-1 receptor agonist” may be defined as acompound which is capable of binding to the GLP-1 receptor and capableof activating it. And a “full” GLP-1 receptor agonist may be defined asa GLP-1 receptor agonist which is capable of eliciting a magnitude ofGLP-1 receptor response that is similar to native GLP-1.

Structural Features GLP-1 Like Peptides and Analogues of GLP-1

The term “GLP-1 like peptide” as used herein may be referred to as ananalogue (or variant) of the human glucagon-like peptide-1(GLP-1(7-37)), the sequence of which is included in the sequence listingas SEQ ID NO: 1. The peptide having the sequence of SEQ ID NO: 1 mayalso be designated “native” GLP-1.

The GLP-1 like peptide of the invention may be defined by the followingformula I:

Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-IIe-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,

wherein Xaa₇ is L-histidine,(S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid, D-histidine,desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine; Xaa₈ is Ala, Gly, Ser, Aib,(1-aminocyclopropyl) carboxylic acid, or (1-aminocyclobutyl) carboxylicacid; Xaa₁₂ is Phe or Leu; Xaa₁₆ is Val or Leu; Xaa₁₈ is Ser, Arg, Lys,Val, or Leu; Xaa₁₉ is Tyr or Gln; Xaa₂₀ is Leu or Met; Xaa₂₂ is Gly orGlu; Xaa₂₃ is Gln, Glu, Lys, or Arg; Xaa₂₅ is Ala or Val; Xaa₂₆ is Argor Lys; Xaa₂₇ is Glu, Lys, or Leu; Xaa₃₀ is Ala, Glu, or Arg; Xaa₃₁ isTrp, Lys, or His; Xaa₃₃ is Val, Lys, or Arg; Xaa₃₄ is Lys, Arg, His,Asn, or Gln; Xaa₃₅ is Gly or Ala; Xaa₃₆ is Arg, Lys, or Gly; Xaa₃₇ isGly or Pro; Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys; Xaa₃₉ is Ser, Gly,Ala, Glu, or Pro; Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₁ is Ser,Gly, Ala, Glu, or Pro; and Xaa₄₂ is Lys; with the proviso that at leastone of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys.

In this formula the numbering of the amino acid residues follows theestablished practice in the art for native GLP-1, namely that the first(N-terminal) amino acid residue is numbered or accorded position no. 7,and the subsequent amino acid residues downstream towards the C-terminusare numbered 8, 9, 10, and so on, until the last (C-terminal) amino acidresidue, which in native GLP-1 is Gly with number 37, however thepeptide of formula I has a C-terminal tail or extension, as defined inthe formula, up to and including position 42.

The numbering is done differently in the sequence listing, where thefirst amino acid residue of (SEQ ID NO: 1 (His) is assigned no. 1, andthe last (Gly) no. 31, and vice versa for the other GLP-1 sequences ofthe sequence listing. However, herein we follow the establishednumbering practice in the art, as explained above.

Each of the GLP-1 analogues of the derivatives of the invention may bedescribed by reference to i) the number of the amino acid residue innative GLP-1(7-37) which corresponds to the amino acid residue which ischanged (i.e., the corresponding position in native GLP-1), and to ii)the actual change.

In other words, the GLP-1 analogue of the invention may be described byreference to the native GLP-1(7-37) peptide, namely as a variant thereofin which a number of amino acid residues have been changed when comparedto native GLP-1(7-37) (SEQ ID NO: 1). These changes may represent,independently, one or more amino acid substitutions, additions, and/ordeletions.

The following are non-limiting examples of suitable analoguenomenclature:

The GLP-1 like peptide incorporated in the derivative of Example 3herein may be referred to as the following GLP-1 analogue: (8Aib, 22E,26R, 34R, 38K, 39G, 40G, 41S, 42K) GLP-1(7-37). This means that whenthis analogue is aligned with native GLP-1, it has i) an Aib at theposition in the analogue which corresponds, according to the alignment,to position 8 in native GLP-1, ii) an E at the position in the analoguewhich corresponds to position 22 in native GLP-1, iii) an R at theposition in the analogue which corresponds to position 26 in nativeGLP-1, iv) an R at the position in the analogue which corresponds toposition 34 in native GLP-1, v) a K at the position in the analoguewhich would correspond to position 38 in native GLP-1 (if extended atthe C-terminus), vi) a G at the position in the analogue which wouldcorrespond to position 39 in native GLP-1 (if extended at theC-terminus), vii) a G at the position in the analogue which wouldcorrespond to position 40 in native GLP-1 (if extended at theC-terminus), iix) an S at the position in the analogue which wouldcorrespond to position 41 in native GLP-1 (if extended at theC-terminus), and ix) a K at the position in the analogue which wouldcorrespond to position 42 in native GLP-1 (if extended at theC-terminus). All other amino acids in this analogue are identical to thecorresponding amino acid in native GLP-1. As explained above, the GLP-1like peptide of the invention may be defined by amino acid changes whenand as compared to native GLP-1. The amino acid changes discussed abovemay be thought of as amino acid substitutions and amino acid additions,relative to native GLP-1. In this example the additions are at theC-terminus, and they may thus also be referred to as C-terminalextensions. For example, 38K refers to the amino acid K being found atthe position C-terminally next to the position which corresponds toposition 37 in native GLP-1, when the analogue is aligned with nativeGLP-1. And then follows at the next position C-terminally G at theposition in the analogue which would correspond to position 39 of nativeGLP-1; and another G at the subsequent position C-terminally, in theposition in the analogue which would correspond to position 40 of nativeGLP-1; and an S at the subsequent position C-terminally, in the positionin the analogue which would correspond to position 41 of native GLP-1,and lastly a K at the position which would correspond to position 42 ofnative GLP-1.

The general formula I is to be understood in a similar manner.

In a particular embodiment at least one of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁,Xaa₃₆, or Xaa₃₈ in formula I is Lys. The GLP-1 like peptide of theinvention comprises at least one more Lys residue, namely at position 42(Xaa₄₂). The latter (pos. 42) may be referred to as the first K residue,and the former, i.e. a Lys at one of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆,or Xaa₃₈, may be referred to as the second K residue. The first and thesecond K residue constitute two acylation sites of the double-acylatedderivative of the invention. The GLP-1 like peptide of the invention maycomprise additional Lys residues, as it is clear from Formula I. In aparticular embodiment the GLP-1 like peptide of the invention has onlytwo Lys residues.

Analogues “comprising” certain specified changes may comprise furtherchanges, when compared to SEQ ID NO: 1. In a particular embodiment, theanalogue “has” the specified changes.

As is apparent from the above examples, amino acid residues may beidentified by their full name, their one-letter code, and/or theirthree-letter code. These three ways are fully equivalent.

The expressions “a position equivalent to” or “corresponding position”may be used to characterise the site of change in a variant GLP-1(7-37)sequence by reference to a reference sequence such as native GLP-1(7-37)(SEQ ID NO: 1). Equivalent or corresponding positions, as well as thenumber of changes, are easily deduced, e.g. by simple handwriting andeyeballing; and/or a standard protein or peptide alignment program maybe used, such as “align” which is based on a Needleman-Wunsch algorithm.This algorithm is described in Needleman, S. B. and Wunsch, C. D.,(1970), Journal of Molecular Biology, 48: 443-453, and the align programby Myers and W. Miller in “Optimal Alignments in Linear Space” CABIOS(computer applications in the biosciences) (1988) 4:11-17. For thealignment, the default scoring matrix BLOSUM62 and the default identitymatrix may be used, and the penalty for the first residue in a gap maybe set at −12, or preferably at −10, and the penalties for additionalresidues in a gap at −2, or preferably at −0.5.

An example of such alignment is inserted below, in which sequence no. 1is SEQ ID NO: 1, and sequence no. 2 is the analogue (8Aib, 22E, 26R,34R, 38K, 39G, 40G, 41S, 42K) thereof:

# Aligned_sequences:   2 # sequence 1:   1 # sequence 2:   2 # Matrix:EBLOSUM62 # Gap_penalty:  10.0 # Extend_penalty:   0.5 # # Length:  36 #Identity:  27/36 (75.0%) # Similarity:  29/36 (80.6%) # Gaps:  5/36 (13.9%) # Score: 143.0 11 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG----- 31  |.|||||||||||||.|||:|||||||:||| 21 HXEGTFTSDVSSYLEEQAAREFIAWLVRGRGKGGSK 36

When 6 is added to the position numbers shown in this alignment (i.e.,to “1” and “31” in sequence 1, and to “1” and “37” in sequence 2) onegets the position numbering as used herein. For example, in sequence 1(which is identical to SEQ ID NO: 1), the N-terminal amino acid (H) hasposition number 7, and the C-terminal amino acid (G) has number 37.Regarding sequence 2, the N-terminal amino acid (H) has number 7 and theC-terminal amino acid (K) has number 42.

In case specific amino acid residues or the like with no one-lettercodon (such as Aib) are included in the sequence these may, foralignment purposes, be replaced with, e.g., X, as shown in the abovealignment. If desired, X can later be manually corrected.

The following are non-limiting examples of what can be inferred from theabove alignment:

As one example it can be inferred that sequence 2 has 9 amino acidchanges as compared to sequence 1 (namely at all those positions where afull stop (“.”), a colon (“:”), or a horizontal hyphen (“-”) is shown inthe alignment).

As another example it can be inferred that, e.g., sequence no. 2comprises 38K, since it has a K at the position which corresponds,according to the alignment, to position 38 in the reference sequence(sequence 1, SEQ ID NO: 1).

And similarly all other changes in sequence 2 as compared to sequence 1can be deduced from the alignment.

The term “peptide”, as e.g. used in the context of the GLP-1 likepeptide of the derivatives of the invention, refers to a compound whichcomprises a series of amino acids interconnected by amide (or peptide)bonds.

The peptide of the invention comprises at least 36 amino acids. In aparticular embodiment the peptide is composed of 36 amino acids. In anadditional particular embodiment the peptide consists of 36 amino acids.

In a still further particular embodiment the peptide consists of aminoacids interconnected by peptide bonds.

Amino acids are molecules containing an amine group and a carboxylicacid group, and, optionally, one or more additional groups, oftenreferred to as a side chain.

The term “amino acid” includes proteinogenic (or natural) amino acids(amongst those the 20 standard amino acids), as well asnon-proteinogenic (or non-natural) amino acids. Proteinogenic aminoacids are those which are naturally incorporated into proteins. Thestandard amino acids are those encoded by the genetic code.Non-proteinogenic amino acids are either not found in proteins, or notproduced by standard cellular machinery (e.g., they may have beensubject to post-translational modification). Non-limiting examples ofnon-proteinogenic amino acids are Aib (α-aminoisobutyric acid, or2-Aminoisobutyric acid), des-amino-histidine (alternative nameimidazopropionic acid or 3-(Imidazol-5-yl)propanoic acid, abbreviatedImp), as well as the D-isomers of the proteinogenic amino acids.

In what follows, each amino acid of the GLP-1 peptide for which theoptical isomer is not stated is to be understood to mean the L-isomer(unless otherwise specified).

The GLP-1 derivatives and analogues of the invention have GLP-1activity. This term refers to the ability to bind to the GLP-1 receptorand initiate a signal transduction pathway resulting in insulinotropicaction or other physiological effects as is known in the art. Forexample, the analogues and derivatives of the invention can be testedfor GLP-1 activity using the assays described in Examples 29, 30, 32, or33 herein.

Derivatives of GLP-1 Like Peptides

The term “GLP-1 derivative” generally refers to a compound which may beprepared from the native GLP-1 peptide or an analogue thereof bychemical modification, in particular by covalent attachment of one ormore substituents. The derivative of a GLP-1 like peptide according tothe invention comprises two such substituents. Each of these may, alsoor alternatively, be referred to as a side chain.

In a particular embodiment, the side chain is capable of formingnon-covalent complexes with albumin, thereby promoting the circulationof the derivative with the blood stream, and also having the effect ofprotracting the time of action of the derivative, due to the fact thatthe complex of the GLP-1-derivative and albumin is only slowlydisintegrated to release the active pharmaceutical ingredient. Thus, thesubstituent, or side chain, as a whole is preferably referred to as analbumin binding moiety.

In another particular embodiment the albumin binding moiety comprises aportion which is particularly relevant for the albumin binding andthereby the protraction, which portion may accordingly be referred to asa protracting moiety. The protracting moiety may be near, preferably at,the terminal (or distal, or free) end of the albumin binding moiety,relative to its point of attachment to the peptide. The albumin bindingmoiety is attached to the peptide by acylation of a lysine residue ofthe peptide, in particular by acylation to the epsilon-amino group ofthe lysine residue.

In a still further particular embodiment the albumin binding moietycomprises a portion between the protracting moiety and the point ofattachment to the peptide, which portion may be referred to as a linker,linker moiety, spacer, or the like.

The derivatives of the invention comprise a first and a secondprotracting moiety of formula Chem. 1, Chem. 1a, or Chem. 1b:

HOOC—(CH₂)₁₈—CO—*,  Chem. 1:

HOOC—(CH₂)₁₇—CO—*, or  Chem. 1a:

HOOC—(CH₂)₂₀—CO—*;  Chem. 1b:

which may also be referred to as C20 diacid, C19 diacid, and C22 diacid,respectively. The first protracting moiety is connected to the first Kresidue, and the second protracting moiety is connected to the second Kresidue. The term “connected” is intended to include direct as well asindirect attachment. An example of indirect attachment is attachment viaa linker placed between the protracting moiety and the K residue. Anexample of direct attachment is when there is no such interveninglinker.

Thus, in a particular embodiment the first protracting moiety isattached to the first K residue, and the second protracting moiety isattached to the second K residue, optionally via a first and a secondlinker, respectively.

The first and the second linker may comprise an element_1, which is aGlu di-radical of formula Chem. 2:

This element may be referred to as gamma-Glu, or briefly gGlu, due tothe fact that it is the gamma carboxy group of the amino acid glutamicacid which is here used for connection to another linker element, or tothe epsilon-amino group of lysine, as the case may be.

Also, or alternatively, the first and the second linker may comprise anelement_2 of formula Chem. 3:

wherein k is an integer in the range of 1-5, and n is an integer in therange of 1-5. In a particular embodiment, when k=1 and n=1, the Chem. 3element_2 may be designated OEG, or a di-radical of8-amino-3,6-dioxaoctanoic acid. In an additional non-limiting particularembodiment k=3 and n=2, in which case the element_2 group of Chem. 3 maybe designated dPEG4.

Also, or alternatively, the first and the second linker may comprise anelement_3 of formula Chem. 4, which may be referred to as Trx (fortranexamic acid):

Also, or alternatively, the first and the second linker may comprise anelement_4 of formula Chem. 5: *—NH—(CH₂)_(q)—CH[(CH₂)_(w)—NH₂]—CO—*,wherein q is an integer in the range of 0-5, and w is an integer in therange of 0-5, with the provisos that when w is 0 q is an integer in therange of 1-5, and when q is 0 w is an integer in the range of 1-5.

Also, or alternatively, the first and the second linker may comprise anelement_5 of formula Chem. 6:

wherein y is 1 or 2, z is 1 or 2, p is 0 or 1, and X designates a carbonatom or an oxygen atom.

Particular non-limiting embodiments of element_5 are Chem, 7, Chem. 8,and Chem. 9:

Also, or alternatively, the first and the second linker may comprise anelement_6 of formula Chem. 10:

The first and the second protracting moieties are connected to the firstand the second linkers, respectively, and in turn to the first and thesecond K residue, respectively, of the GLP-1 like peptide via amidebonds.

The first and the second linker may comprise one or more of the variouselements as defined above (element_1 to element_6), each element mayoccur one or more times, and also the sequence of the elements may vary.

Whenever a linker is said to “comprise” a certain element, it may inaddition contain other elements, whereas the term “incorporates” isintended to mean the same as “has” or “includes only”. Therefore, alinker which “incorporates” two elements_2 of formula Chem. 3 has onlytwo of these elements in its structure.

Various particular combinations of linker elements are described in moredetail below in the section headed “Particular embodiments”. Thesequence in which the elements are indicated here is generally from theN-terminus to the C-terminus.

In a particular embodiment, the two albumin binding moieties (i.e. thetwo side chains) are similar, preferably substantially identical, or,most preferably, identical.

In another particular embodiment, the first and the second protractingmoieties are similar, preferably substantially identical, or, mostpreferably, identical.

In a still further particular embodiment, the first and the secondlinkers are similar, preferably substantially identical, or, mostpreferably identical.

The term “substantially identical” includes differences from identitywhich are due to formation of one or more esters and/or amides;preferably formation of one or more methyl esters, and simple amides;more preferably formation of no more than two methyl esters, and/orsimple amides; or most preferably formation of no more than one methylester, and/or simple amide.

In the context of chemical compounds such as the albumin bindingmoieties, protracting moieties, and linkers, similarity and/or identitymay be determined using any suitable computer program and/or algorithmknown in the art.

For example, the similarity of two protracting moieties, two linkers,and/or two entire side chains may suitably be determined using molecularfingerprints. Fingerprints is a mathematical method of representing achemical structure (see e.g. Chemoinformatics: A textbook, JohannGasteiger and Thomas Engel (Eds), Wiley-VCH Verlag, 2003).

Examples of suitable fingerprints include, without limitation, UNITYfingerprints, MDL fingerprints, and/or ECFP fingerprints, such as ECFP_6fingerprints (ECFP stands for extended-connectivity fingerprints).

In particular embodiments, the two protracting moieties, the twolinkers, and/or the two entire side chains are represented as a) ECFP_6fingerprints; b) UNITY fingerprints; and/or c) MDL fingerprints.

The Tanimoto coefficient is preferably used for calculating thesimilarity of the two fingerprints, whether a), b), or c) is used.

In particular embodiments, whether a), b), or c) is used, the twoprotracting moieties, the two linkers, and/or the two entire sidechains, respectively, have a similarity of at least 0.5 (50%);preferably at least 0.6 (60%); more preferably at least 0.7 (70%), or atleast 0.8 (80%); even more preferably at least 0.9 (90%); or mostpreferably at least 0.99 (99%), such as a similarity of 1.0 (100%).

UNITY fingerprints may be calculated using the programme SYBYL(available from Tripos, 1699 South Hanley Road, St. Louis, Mo.63144-2319 USA). ECFP_6 and MDL fingerprints may be calculated using theprogramme Pipeline Pilot (available from Accelrys Inc., 10188 TelesisCourt, Suite 100, San Diego, Calif. 92121, USA).

For more details, see for example J. Chem. Inf. Model. 2008, 48,542-549; J. Chem. Inf. Comput. Sci. 2004, 44, 170-178; J. Med. Chem.2004, 47, 2743-2749; J. Chem. Inf. Model. 2010, 50, 742-754; as well asSciTegic Pipeline Pilot Chemistry Collection: Basic Chemistry UserGuide, March 2008, SciTegic Pipeline Pilot Data Modeling Collection,2008—both from Accelrys Software Inc., San Diego, US, and the guideshttp://www.tripos.com/tripos_resources/fileroot/pdfs/Unity_111408. pdf,and http://www.tripos.com/data/SYBYL/SYBYL_072505. pdf.

An example of a similarity calculation is inserted below, in which aknown entire side chain of a known GLP-1 derivative was compared with amethyl ester thereof:

Using a) ECFP_6 fingerprints the similarity is 0.798, using b) UNITYfingerprints the similarity is 0.957; and using MDL fingerprints thesimilarity is 0.905.

In case of two identical side chains (albumin binding moieties) thederivative may be designated symmetrical.

In particular embodiments, the similarity coefficient is at least 0.80,preferably at least 0.85, more preferably at least 0.90, even morepreferably at least 0.95, or most preferably at least 0.99.

The derivatives of the invention may exist in different stereoisomericforms having the same molecular formula and sequence of bonded atoms,but differing only in the three-dimensional orientation of their atomsin space. The stereoisomerism of the exemplified derivatives of theinvention is indicated in the experimental section, in the names as wellas the structures, using standard nomenclature. Unless otherwise statedthe invention relates to all stereoisomeric forms of the claimedderivative.

The concentration in plasma of the GLP-1 derivatives of the inventionmay be determined using any suitable method. For example, LC-MS (LiquidChromatography Mass Spectroscopy) may be used, or immunoassays such asRIA (Radio Immuno Assay), ELISA (Enzyme-Linked Immuno Sorbent Assay),and LOCI (Luminescence Oxygen Channeling Immunoasssay). Generalprotocols for suitable RIA and ELISA assays are found in, e.g., WO2009/030738 on p. 116-118. A preferred assay is the LOCI assay, whereLOCI refers to Luminescence Oxygen Channeling Immunoasssay, which isgenerally described for the determination of insulin by Poulsen andJensen in Journal of Biomolecular Screening 2007, vol. 12, p. 240-247.The donor beads were coated with streptavidin, while acceptor beads wereconjugated with a monoclonal antibody recognising a mid-/C-terminalepitope of the peptide. Another monoclonal antibody, specific for theN-terminus, was biotinylated. The three reactants were combined with theanalyte and formed a two-sited immuno-complex. Illumination of thecomplex released singlet oxygen atoms from the donor beads, which werechanneled into the acceptor beads and triggered chemiluminescence whichwas measured in an Envision plate reader. The amount of light wasproportional to the concentration of the compound.

Pharmaceutically Acceptable Salt, Amide, or Ester

The derivatives, analogues, and intermediate products of the inventionmay be in the form of a pharmaceutically acceptable salt, amide, orester.

Salts are e.g. formed by a chemical reaction between a base and an acid,e.g.: 2NH₃+H₂SO₄→(NH₄)₂SO₄.

The salt may be a basic salt, an acid salt, or it may be neither nor(i.e. a neutral salt). Basic salts produce hydroxide ions and acid saltshydronium ions in water.

The salts of the derivatives of the invention may be formed with addedcations or anions between anionic or cationic groups, respectively.These groups may be situated in the peptide moiety, and/or in the sidechain of the derivatives of the invention.

Non-limiting examples of anionic groups of the derivatives of theinvention include free carboxylic groups in the side chain, if any, aswell as in the peptide moiety. The peptide moiety often includes a freecarboxylic acid group at the C-terminus, and it may also include freecarboxylic groups at internal acid amino acid residues such as Asp andGlu.

Non-limiting examples of cationic groups in the peptide moiety includethe free amino group at the N-terminus, if present, as well as any freeamino group of internal basic amino acid residues such as His, Arg, andLys.

In a particular embodiment the derivatives and analogues of theinvention are basic salts. The salts may, e.g., be formed betweenanionic groups in the peptide moiety and added sodium or potassiumcations.

The ester of the derivatives of the invention may, e.g., be formed bythe reaction of a free carboxylic acid group with an alcohol or aphenol, which leads to replacement of at least one hydroxyl group by analkoxy or aryloxy group

The ester formation may involve the free carboxylic group at theC-terminus of the peptide, and/or any free carboxylic group in the sidechain.

The amide of the derivatives of the invention may, e.g., be formed bythe reaction of a free carboxylic acid group with an amine or asubstituted amine, or by reaction of a free or substituted amino groupwith a carboxylic acid.

The amide formation may involve the free carboxylic group at theC-terminus of the peptide, any free carboxylic group in the side chain,the free amino group at the N-terminus of the peptide, and/or any freeor substituted amino group of the peptide in the peptide and/or the sidechain.

In a particular embodiment, the peptide or derivative is in the form ofa pharmaceutically acceptable salt. In another particular embodiment,the derivative is in the form of a pharmaceutically acceptable amide,preferably with an amide group at the C-terminus of the peptide. In astill further particular embodiment, the peptide or derivative is in theform a pharmaceutically acceptable ester.

Functional Properties

In a particular embodiment the derivatives of the invention have a verylong half-life and at the same time a very good potency in vitro and invivo, which makes them potentially suitable for once-monthlyadministration.

Thus, in a first functional aspect, the derivatives of the inventionhave a good potency. Also, or alternatively, in a second aspect, theybind very well to the GLP-1 receptor, e.g. at a high concentration ofalbumin. Preferably they are potent GLP-1 receptor agonists as isreflected by their ability to bind strongly to the GLP-1 receptorcombined with the capacity to activate the receptor. Also, oralternatively, in a third functional aspect, they have improvedpharmacokinetic properties.

Biological Activity—In Vitro Potency

According to the first functional aspect, the derivatives of theinvention, as well as the constituent GLP-1 like peptides as such, arebiologically active, or potent.

In a particular embodiment, potency and/or activity refers to in vitropotency, i.e. performance in a functional GLP-1 receptor assay, more inparticular to the capability of activating the human GLP-1 receptor.

The in vitro potency may, e.g., be determined in a medium containingmembranes expressing the human GLP-1 receptor, and/or in an assay withwhole cells expressing the human GLP-1 receptor.

For example, the response of the human GLP-1 receptor may be measured ina reporter gene assay, e.g. in a stably transfected BHK cell line thatexpresses the human GLP-1 receptor and contains the DNA for the cAMPresponse element (CRE) coupled to a promoter and the gene for fireflyluciferase (CRE luciferase). When cAMP is produced as a result ofactivation of the GLP-1 receptor this in turn results in the luciferasebeing expressed. Luciferase may be determined by adding luciferin, whichby the enzyme is converted to oxyluciferin and produces bioluminescence,which is measured and is a measure of the in vitro potency. Onenon-limiting example of such an assay is described in Example 29.

The term half maximal effective concentration (EC₅₀) generally refers tothe concentration which induces a response halfway between the baselineand maximum, by reference to the dose response curve. EC₅₀ is used as ameasure of the potency of a compound and represents the concentrationwhere 50% of its maximal effect is observed.

The in vitro potency of the derivatives of the invention may bedetermined as described above, and the EC₅₀ of the derivative inquestion determined. The lower the EC₅₀ value, the better the potency.

In a particular embodiment, the derivatives of the invention are verypotent, despite the fact that they have very long half-lives. In aparticular embodiment, the derivative of the invention has an in vitropotency determined using the method of Example 29 corresponding to anEC₅₀ at or below 400 pM.

Biological Activity—In Vivo Pharmacology

In another particular embodiment the derivatives of the invention aswell as the constituent GLP-1 like peptides as such are potent in vivo,which may be determined as is known in the art in any suitable animalmodel, as well as in clinical trials.

The diabetic db/db mouse is one example of a suitable animal model, andthe blood glucose and/or body weight lowering effect may be determinedin such mice in vivo, e.g. as described in Example 32. In a particularembodiment the derivatives of the invention are capable of loweringblood glucose and body weight in db/db mice for at least up to 96 hours.

The LYD pig is another example of a suitable animal model, and thereduction in food intake may be determined in a PD study in such pigs invivo, e.g. as described in Example 33.

In a particular embodiment the derivatives of the invention are verypotent in vivo and over a long time, which is evidenced by the resultsfound in the experimental part and also referred to in the sectionheaded “Particular embodiments”.

Biological Activity—In Vitro Receptor Binding

According to the second functional aspect, the derivatives of theinvention, as well as the constituent GLP-1 like peptides as such bindvery well to the GLP-1 receptor, e.g. at a high concentration ofalbumin. This may be determined as described in Example 30.

Generally, the binding to the GLP-1 receptor at low albuminconcentration should be as good as possible, corresponding to a low IC₅₀value.

The IC₅₀ value at high albumin concentration reflects the influence ofserum albumin on the binding of the derivative to the GLP-1 receptor. Asis known, the GLP-1 derivatives can bind to serum albumin and if this isthe case then the IC₅₀ value at high serum albumin will be higher thanthe IC₅₀ value at low albumin. An increased IC₅₀ value at high serumalbumin represents a reduced binding to the GLP-1 receptor caused byserum albumin binding competing with the binding to the GLP-1 receptor.

In a particular embodiment, the derivatives of the invention bind verywell to the GLP-1 receptor at a low albumin concentration, but they alsobind very well at a high albumin concentration.

As an example, in a particular embodiment, the GLP-1 receptor bindingaffinity (IC₅₀) of the derivatives of the invention in the presence of alow concentration of HSA (low albumin) is at 5.0 nM or below.

Pharmacokinetics Profile

According to the third functional aspect, the derivatives of theinvention have improved pharmacokinetic properties such as increasedterminal half-life, and/or decreased clearance.

Increasing terminal half-life and/or decreasing of the clearance meansthat the compound in question is eliminated slower from the body. Forthe derivatives of the invention this entails an extended duration ofpharmacological effect.

The pharmacokinetic properties of the derivatives of the invention maysuitably be determined in-vivo in pharmacokinetic (PK) studies. Suchstudies are conducted to evaluate how pharmaceutical compounds areabsorbed, distributed, and eliminated in the body, and how theseprocesses affect the concentration of the compound in the body, over thecourse of time.

In the discovery and preclinical phase of pharmaceutical drugdevelopment, animal models such as the mouse, rat, monkey, dog, or pig,may be used to perform this characterisation. Any of these models can beused to test the pharmacokinetic properties of the derivatives of theinvention.

In such studies, animals are typically administered with a single doseof the drug, either intravenously (i.v.), subcutaneously (s.c.), ororally (p.o.) in a relevant formulation. Blood samples are drawn atpredefined time points after dosing, and samples are analysed forconcentration of drug with a relevant quantitative assay. Based on thesemeasurements, time-plasma concentration profiles for the compound ofstudy are plotted and a so-called non-compartmental pharmacokineticanalysis of the data is performed.

For most compounds, the terminal part of the plasma-concentrationprofiles will be linear when drawn in a semi-logarithmic plot,reflecting that after the initial absorption and distribution, drug isremoved from the body at a constant fractional rate. The rate (lambda Zor λ_(z)) is equal to minus the slope of the terminal part of the plot.From this rate, also a terminal half-life may be calculated, ast½=ln(2)/λ_(z) (see, e.g., Johan Gabrielsson and Daniel Weiner:Pharmacokinetics and Pharmacodynamic Data Analysis. Concepts &Applications, 3rd Ed., Swedish Pharmaceutical Press, Stockholm (2000)).

Clearance can be determined after i.v. administration and is defined asthe dose (D) divided by area under the curve (AUC) on the plasmaconcentration versus time profile (Rowland, M and Tozer T N: ClinicalPharmacokinetics: Concepts and Applications, 3^(rd) edition, 1995Williams Wilkins).

The estimate of terminal half-life and/or clearance is relevant forevaluation of dosing regimens and an important parameter in drugdevelopment, in the evaluation of new drug compounds.

Pharmacokinetics Profile—Half Life In Vivo in Minipigs

According to the third functional aspect, the derivatives of theinvention have improved pharmacokinetic properties.

In a particular embodiment, the pharmacokinetic properties may bedetermined as terminal half-life (T_(1/2)) in vivo in minipigs afteri.v. administration, e.g. as described in Example 31 herein.

In a particular embodiment the derivatives of the invention have anexcellent terminal half-life in minipigs which makes them suitable foronce-monthly administration. In a particular embodiment, the terminalhalf-life of the derivatives of the invention in minipigs after i.v.administration is at least 90 hours.

Additional particular embodiments of the derivatives of the inventionare described in the section headed “Particular embodiments” before theexperimental section.

Production Processes

The production of peptides like GLP-1(7-37) and GLP-1 analogues is wellknown in the art.

The GLP-1 like peptide moiety of the derivatives of the invention (orfragments thereof) may for instance be produced by classical peptidesynthesis, e.g., solid phase peptide synthesis using t-Boc or Fmocchemistry or other well established techniques, see, e.g., Greene andWuts, “Protective Groups in Organic Synthesis”, John Wiley & Sons, 1999,Florencio Zaragoza Dörwald, “Organic Synthesis on solid Phase”,Wiley-VCH Verlag GmbH, 2000, and “Fmoc Solid Phase Peptide Synthesis”,Edited by W. C. Chan and P. D. White, Oxford University Press, 2000.

Also, or alternatively, they may be produced by recombinant methods,viz. by culturing a host cell containing a DNA sequence encoding theanalogue and capable of expressing the peptide in a suitable nutrientmedium under conditions permitting the expression of the peptide.Non-limiting examples of host cells suitable for expression of thesepeptides are: Escherichia coli, Saccharomyces cerevisiae, as well asmammalian BHK or CHO cell lines.

Those derivatives of the invention which include non-natural amino acidsand/or a covalently attached N-terminal mono- or dipeptide mimetic maye.g. be produced as described in the experimental part. Or see e.g.,Hodgson et al: “The synthesis of peptides and proteins containingnon-natural amino acids”, Chemical Society Reviews, vol. 33, no. 7(2004), p. 422-430; and WO 2009/083549 A1 entitled “Semi-recombinantpreparation of GLP-1 analogues”.

Specific examples of methods of preparing a number of the derivatives ofthe invention are included in the experimental part.

Pharmaceutical Compositions

The invention also relates to pharmaceutical compositions comprising aderivative of the invention or a pharmaceutically acceptable salt,amide, or ester thereof, and a pharmaceutically acceptable excipient.Such compositions may be prepared as is known in the art.

The term “excipient” broadly refers to any component other than theactive therapeutic ingredient(s). The excipient may be an inertsubstance, an inactive substance, and/or a not medicinally activesubstance.

The excipient may serve various purposes, e.g. as a carrier, vehicle,diluent, tablet aid, and/or to improve administration, and/or absorptionof the active substance.

The formulation of pharmaceutically active ingredients with variousexcipients is known in the art, see e.g. Remington: The Science andPractice of Pharmacy (e.g. 19^(th) edition (1995), and any latereditions).

Non-limiting examples of excipients are: Solvents, diluents, buffers,preservatives, tonicity regulating agents, chelating agents, andstabilisers.

Examples of formulations include liquid formulations, i.e. aqueousformulations comprising water. A liquid formulation may be a solution,or a suspension. An aqueous formulation typically comprises at least 50%w/w water, or at least 60%, 70%, 80%, or even at least 90% w/w of water.

Alternatively, a pharmaceutical composition may be a solid formulation,e.g. a freeze-dried or spray-dried composition, which may be used as is,or whereto the physician or the patient adds solvents, and/or diluentsprior to use.

The pH in an aqueous formulation may be anything between pH 3 and pH 10,for example from about 7.0 to about 9.5; or from about 3.0 to about 7.0.

A pharmaceutical composition may comprise a buffer. The buffer may e.g.be selected from sodium acetate, sodium carbonate, citrate,glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogenphosphate, disodium hydrogen phosphate, sodium phosphate, andtris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate,maleic acid, fumaric acid, tartaric acid, aspartic acid, and mixturesthereof.

A pharmaceutical composition may comprise a preservative. Thepreservative may e.g. be selected from phenol, o-cresol, m-cresol,p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate,2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzylalcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid,imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethylp-hydroxybenzoate, benzethonium chloride, chlorphenesine(3p-chlorphenoxypropane-1,2-diol), and mixtures thereof. Thepreservative may be present in a concentration from 0.1 mg/ml to 20mg/ml. A pharmaceutical composition may comprise an isotonic agent. Theisotonic agent may e.g. be selected from a salt (e.g. sodium chloride),a sugar or sugar alcohol, an amino acid (e.g. glycine, histidine,arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), analditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol),1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), andmixtures thereof. Any sugar such as mono-, di-, or polysaccharides, orwater-soluble glucans, including for example fructose, glucose, mannose,sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran,pullulan, dextrin, cyclodextrin, alfa and beta HPCD, soluble starch,hydroxyethyl starch and carboxymethylcellulose-Na may be used. Sugaralcohol is defined as a C4-C8 hydrocarbon having at least one —OH groupand includes, for example, mannitol, sorbitol, inositol, galactitol,dulcitol, xylitol, and arabitol. In one embodiment, the sugar alcoholadditive is mannitol.

A pharmaceutical composition may comprise a chelating agent. Thechelating agent may e.g. be selected from salts ofethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid,and mixtures thereof.

A pharmaceutical composition may comprise a stabiliser. The stabilisermay e.g. be one or more oxidation inhibitors, aggregation inhibitors,surfactants, and/or one or more protease inhibitors. Non-limitingexamples of these various kinds of stabilisers are disclosed in thefollowing.

The term “aggregate formation” refers to a physical interaction betweenthe polypeptide molecules resulting in formation of oligomers, which mayremain soluble, or large visible aggregates that precipitate from thesolution. Aggregate formation by a polypeptide during storage of aliquid pharmaceutical composition can adversely affect biologicalactivity of that polypeptide, resulting in loss of therapeutic efficacyof the pharmaceutical composition. Furthermore, aggregate formation maycause other problems such as blockage of tubing, membranes, or pumpswhen the polypeptide-containing pharmaceutical composition isadministered using an infusion system.

A pharmaceutical composition may comprise an amount of an amino acidbase sufficient to decrease aggregate formation of the polypeptideduring storage of the composition. The term “amino acid base” refers toone or more amino acids (such as methionine, histidine, imidazole,arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), oranalogues thereof. Any amino acid may be present either in its free baseform or in its salt form. Any stereoisomer (i.e., L, D, or a mixturethereof) of the amino acid base may be present.

Methionine (or other sulphuric amino acids or amino acid analogous) maybe added to inhibit oxidation of methionine residues to methioninesulfoxide when the polypeptide acting as the therapeutic agent is apolypeptide comprising at least one methionine residue susceptible tosuch oxidation. Any stereoisomer of methionine (L or D) or combinationsthereof can be used.

A pharmaceutical composition may comprise a stabiliser selected fromhigh molecular weight polymers or low molecular compounds. Thestabiliser may e.g. be selected from polyethylene glycol (e.g. PEG3350), polyvinyl alcohol (PVA), polyvinylpyrrolidone,carboxy-/hydroxycellulose or derivates thereof (e.g. HPC, HPC-SL, HPC-Land HPMC), cyclodextrins, sulphur-containing substances asmonothioglycerol, thioglycolic acid and 2-methylthioethanol, anddifferent salts (e.g. sodium chloride). A pharmaceutical composition maycomprise additional stabilising agents such as, but not limited to,methionine and EDTA, which protect the polypeptide against methionineoxidation, and a nonionic surfactant, which protects the polypeptideagainst aggregation associated with freeze-thawing or mechanicalshearing.

A pharmaceutical composition may comprise one or more surfactants. Theterm “surfactant” refers to any molecules or ions that are comprised ofa water-soluble (hydrophilic) part, and a fat-soluble (lipophilic) part.The surfactant may e.g. be selected from anionic surfactants, cationicsurfactants, nonionic surfactants, and/or zwitterionic surfactants.

A pharmaceutical composition may comprise one or more proteaseinhibitors, such as, e.g., EDTA (ethylenediamine tetraacetic acid),and/or benzamidineHCl.

Additional, optional, ingredients of a pharmaceutical compositioninclude, e.g., wetting agents, emulsifiers, antioxidants, bulkingagents, metal ions, oily vehicles, proteins (e.g., human serum albumin,gelatine), and/or a zwitterion (e.g., an amino acid such as betaine,taurine, arginine, glycine, lysine and histidine).

As stated above the present invention also relates to pharmaceuticalcompositions comprising a derivative of the invention or apharmaceutically acceptable salt, amide, or ester thereof, and apharmaceutically acceptable excipient.

In a particular embodiment, the excipient comprises a phosphate bufferand an isotonic agent.

In another particular embodiment, the excipient comprises a phosphatebuffer and propylene glycol ad isotoni.

In a still further particular embodiment the invention relates to asingle dose pharmaceutical composition for s.c. injection whichcomprises (i) a GLP-1 derivative of the invention or a pharmaceuticallyacceptable salt, amide, or ester thereof, in a suitable concentration,(ii) an 8 mM phosphate buffer (such as 1.42 mg/mL Disodium PhosphateDihydrate), (iii) propylene glycol ad isotoni, and (iv) which has a pHof 7.4.

The term “suitable concentration” refers to a pharmaceutically relevantconcentration, which may be determined as is known in the art.

Non-limiting examples of suitable concentrations correspond to theadministered doses mentioned below, when contained in 1 mL of thecomposition (i.e., e.g. a suitable concentration may be from 0.1 mg/mLto 100 mg/mL of the composition).

In a particular embodiment, the suitable concentration is 3 mg/mL.

In another particular embodiment, the suitable concentration is 30mg/mL.

In still further particular embodiments the GLP-1 derivative is (a) thecompound of Example 1, (b) the compound of Example 2, (c) the compoundof Example 3, (d) the compound of Example 5, or a pharmaceuticallyacceptable salt, amide, or ester of any of (a)-(d).

Still further, a pharmaceutical composition may be formulated as isknown in the art of oral formulations of insulinotropic compounds, e.g.using any one or more of the formulations described in WO 2008/145728.

An administered dose may contain from 0.1 mg-100 mg of the derivative,from 1-100 mg of the derivative, or from 1-50 mg of the derivative.

The derivative may be administered in the form of a pharmaceuticalcomposition. It may be administered to a patient in need thereof atseveral sites, for example, at topical sites such as skin or mucosalsites; at sites which bypass absorption such as in an artery, in a vein,or in the heart; and at sites which involve absorption, such as in theskin, under the skin, in a muscle, or in the abdomen.

The route of administration may be, for example, lingual; sublingual;buccal; in the mouth; oral; in the stomach; in the intestine; nasal;pulmonary, such as through the bronchioles, the alveoli, or acombination thereof; parenteral, epidermal; dermal; transdermal;conjunctival; uretal; vaginal; rectal; and/or ocular. A composition maybe an oral composition, and the route of administration is per oral.

A composition may be administered in several dosage forms, for exampleas a solution; a suspension; an emulsion; a microemulsion; multipleemulsions; a foam; a salve; a paste; a plaster; an ointment; a tablet; acoated tablet; a chewing gum; a rinse; a capsule such as hard or softgelatine capsules; a suppositorium; a rectal capsule; drops; a gel; aspray; a powder; an aerosol; an inhalant; eye drops; an ophthalmicointment; an ophthalmic rinse; a vaginal pessary; a vaginal ring; avaginal ointment; an injection solution; an in situ transformingsolution such as in situ gelling, setting, precipitating, and in situcrystallisation; an infusion solution; or as an implant.

A composition may be a tablet, optionally coated, a capsule, or achewing gum.

A composition may further be compounded in a drug carrier or drugdelivery system, e.g. in order to improve stability, bioavailability,and/or solubility. In a particular embodiment a composition may beattached to such system through covalent, hydrophobic, and/orelectrostatic interactions. The purpose of such compounding may be,e.g., to decrease adverse effects, achieve chronotherapy, and/orincrease patient compliance.

A composition may also be used in the formulation of controlled,sustained, protracting, retarded, and/or slow release drug deliverysystems.

Parenteral administration may be performed by subcutaneous,intramuscular, intraperitoneal, or intravenous injection by means of asyringe, optionally a pen-like syringe, or by means of an infusion pump.

A composition may be administered nasally in the form of a solution, asuspension, or a powder; or it may be administered pulmonally in theform of a liquid or powder spray.

Transdermal administration is a still further option, e.g. byneedle-free injection, from a patch such as an iontophoretic patch, orvia a transmucosal route, e.g. buccally.

A composition may be a stabilised formulation. The term “stabilisedformulation” refers to a formulation with increased physical and/orchemical stability, preferably both. In general, a formulation must bestable during use and storage (in compliance with recommended use andstorage conditions) until the expiration date is reached.

The term “physical stability” refers to the tendency of the polypeptideto form biologically inactive and/or insoluble aggregates as a result ofexposure to thermo-mechanical stress, and/or interaction withdestabilising interfaces and surfaces (such as hydrophobic surfaces).The physical stability of an aqueous polypeptide formulation may beevaluated by means of visual inspection, and/or by turbiditymeasurements after exposure to mechanical/physical stress (e.g.agitation) at different temperatures for various time periods.Alternatively, the physical stability may be evaluated using aspectroscopic agent or probe of the conformational status of thepolypeptide such as e.g. Thioflavin T or “hydrophobic patch” probes.

The term “chemical stability” refers to chemical (in particularcovalent) changes in the polypeptide structure leading to formation ofchemical degradation products potentially having a reduced biologicalpotency, and/or increased immunogenic effect as compared to the intactpolypeptide. The chemical stability can be evaluated by measuring theamount of chemical degradation products at various time-points afterexposure to different environmental conditions, e.g. by SEC-HPLC, and/orRP-HPLC.

The treatment with a derivative according to the present invention mayalso be combined with one or more additional pharmacologically activesubstances, e.g. selected from antidiabetic agents, antiobesity agents,appetite regulating agents, antihypertensive agents, agents for thetreatment and/or prevention of complications resulting from orassociated with diabetes and agents for the treatment and/or preventionof complications and disorders resulting from or associated withobesity. Examples of these pharmacologically active substances are:Insulin, sulphonylureas, biguanides, meglitinides, glucosidaseinhibitors, glucagon agonists, glucagon antagonists, DPP-IV (dipeptidylpeptidase-IV) inhibitors, inhibitors of hepatic enzymes involved instimulation of gluconeogenesis and/or glycogenolysis, glucose uptakemodulators, compounds modifying the lipid metabolism such asantihyperlipidemic agents as HMG CoA inhibitors (statins), GastricInhibitory Polypeptides (GIP analogs), compounds lowering food intake,RXR agonists and agents acting on the ATP-dependent potassium channel ofthe β-cells; Cholestyramine, colestipol, clofibrate, gemfibrozil,lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine,neteglinide, repaglinide; β-blockers such as alprenolol, atenolol,timolol, pindolol, propranolol and metoprolol, ACE (angiotensinconverting enzyme) inhibitors such as benazepril, captopril, enalapril,fosinopril, lisinopril, alatriopril, quinapril and ramipril, calciumchannel blockers such as nifedipine, felodipine, nicardipine,isradipine, nimodipine, diltiazem and verapamil, and α-blockers such asdoxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamineregulated transcript) agonists, NPY (neuropeptide Y) antagonists, PYYagonists, Y2 receptor agonists, Y4 receptor agonits, mixed Y2/Y4receptor agonists, MC4 (melanocortin 4) agonists, orexin antagonists,TNF (tumor necrosis factor) agonists, CRF (corticotropin releasingfactor) agonists, CRF BP (corticotropin releasing factor bindingprotein) antagonists, urocortin agonists, β3 agonists, oxyntomodulin andanalogues, MSH (melanocyte-stimulating hormone) agonists, MCH(melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin)agonists, serotonin re-uptake inhibitors, serotonin and noradrenalinere-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT(serotonin) agonists, bombesin agonists, fibroblast growth factor 21(FGF-21), galanin antagonists, growth hormone, growth hormone releasingcompounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3(uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists(bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid Xreceptor) modulators, TR β agonists; histamine H3 antagonists, GastricInhibitory Polypeptide agonists or antagonists (GIP analogs), gastrinand gastrin analogs.

The treatment with a derivative according to this invention may also becombined with a surgery that influences the glucose levels, and/or lipidhomeostasis such as gastric banding or gastric bypass.

Pharmaceutical Indications

The present invention also relates to a derivative of the invention, foruse as a medicament.

In particular embodiments, the derivative of the invention may be usedfor the following medical treatments:

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse.

In a particular embodiment the indication is selected from the groupconsisting of (i)-(xiv), such as indications (i)-(viii), (x)-(xiii),and/or (xiv), and relates in one way or the other to diabetes.

In another particular embodiment, the indication is selected from thegroup consisting of (i)-(iii) and (v)-(viii), such as indications (i),(ii), and/or (iii); or indication (v), indication (vi), indication(vii), and/or indication (viii).

In a still further particular embodiment, the indication is (i). In afurther particular embodiment the indication is (v). In a still furtherparticular embodiment the indication is (viii).

The following indications are particularly preferred: Type 2 diabetes,and/or obesity.

Particular Embodiments

The following are particular embodiments of the invention:

1. A derivative of a GLP-1 like peptide, wherein the GLP-1 like peptidecomprises a peptide of formula I:

Formula I: Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,wherein

Xaa₇ is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid,D-histidine, desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine;

Xaa₈ is Ala, Gly, Ser, Aib, (1-aminocyclopropyl) carboxylic acid, or(1-aminocyclobutyl) carboxylic acid;

Xaa₁₂ is Phe or Leu;

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Arg, Lys, Val, or Leu;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys, or Arg;

Xaa₂₅ is Ala or Val;

Xaa₂₆ is Arg or Lys;

Xaa₂₇ is Glu, Lys, or Leu;

Xaa₃₀ is Ala, Glu, or Arg;

Xaa₃₁ is Trp, Lys, or His;

Xaa₃₃ is Val, Lys, or Arg;

Xaa₃₄ is Lys, Arg, His, Asn, or Gln;

Xaa₃₅ is Gly or Ala;

Xaa₃₆ is Arg, Lys, or Gly;

Xaa₃₇ is Gly or Pro;

Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys;

Xaa₃₉ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₁ is Ser, Gly, Ala, Glu, or Pro; and

Xaa₄₂ is Lys;

with the proviso that at least one of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆,or Xaa₃₈ is Lys;

wherein

Lys at Xaa₄₂ is a first K residue, and a Lys at one of Xaa₁₈, Xaa₂₃,Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is a second K residue;

which derivative comprises a first and a second protracting moietyconnected to said first and second K residue, respectively, wherein thefirst and the second protracting moiety is selected from Chem. 1, Chem.1a, and Chem. 1b:

HOOC—(CH₂)₁₈—CO—*,  Chem. 1:

HOOC—(CH₂)₁₇—CO—*, and  Chem. 1a:

HOOC—(CH₂)₂₀—CO—*;  Chem. 1b:

or a pharmaceutically acceptable salt, amide, or ester thereof.2. The derivative of embodiment 1, wherein the GLP-1 like peptidecomprises at least two Lys residues.3. The derivative of any of embodiments 1-2, wherein the GLP-1 likepeptide comprises two Lys residues.4. The derivative of any of embodiments 1-3, wherein the GLP-1 likepeptide has two Lys residues.5. The derivative of any of embodiments 1-4, wherein the GLP-1 likepeptide has only two Lys residues.6. The derivative of any of embodiments 15, wherein one of Xaa₁₈, Xaa₂₃,Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys.7. The derivative of any of embodiments 1-6, wherein only one of Xaa₁₈,Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys.8. The derivative of any of embodiments 1-7, wherein a Lys at Xaa₁₈ isthe second K residue.9. The derivative of any of embodiments 1-8, wherein a Lys at Xaa₂₃ isthe second K residue.10. The derivative of any of embodiments 1-9, wherein a Lys at Xaa₂₇ isthe second K residue.11. The derivative of any of embodiments 1-10, wherein a Lys at Xaa₃₁ isthe second K residue.12. The derivative of any of embodiments 1-11, wherein a Lys at Xaa₃₆ isthe second K residue.13. The derivative of any of embodiments 1-12, wherein a Lys at Xaa₃₈ isthe second K residue.14. The derivative of any of embodiments 1-4, wherein Xaa₇ is His.15. The derivative of any of embodiments 1-14, wherein Xaa₇ isdesamino-histidine.16. The derivative of any of embodiments 1-15, wherein Xaa₈ is Aib.17. The derivative of any of embodiments 1-16, wherein Xaa₁₂ is Phe.18. The derivative of any of embodiments 1-17, wherein Xaa₁₆ is Val.19. The derivative of any of embodiments 1-18, wherein Xaa₁₈ is Ser orLys.20. The derivative of any of embodiments 1-19, wherein Xaa₁₈ is Ser.21. The derivative of any of embodiments 1-19, wherein Xaa₁₈ is Lys.22. The derivative of any of embodiments 1-21, wherein Xaa₁₉ is Tyr.23. The derivative of any of embodiments 1-22, wherein Xaa₂₀ is Leu.24. The derivative of any of embodiments 1-23, wherein Xaa₂₂ is Glu.25. The derivative of any of embodiments 1-24, wherein Xaa₂₃ is Gln orLys.26. The derivative of any of embodiments 1-25, wherein Xaa₂₃ is Gln.27. The derivative of any of embodiments 1-25, wherein Xaa₂₃ is Lys.28. The derivative of any of embodiments 1-27, wherein Xaa₂₅ is Ala.29. The derivative of any of embodiments 1-28, wherein Xaa₂₆ is Arg.30. The derivative of any of embodiments 1-29, wherein Xaa₂₇ is Glu orLys.31. The derivative of any of embodiments 1-30, wherein Xaa₂₇ is Glu.32. The derivative of any of embodiments 1-30, wherein Xaa₂₇ is Lys.33. The derivative of any of embodiments 1-32, wherein Xaa₃₀ is Ala.34. The derivative of any of embodiments 1-33, wherein Xaa₃₁ is Trp orLys.35. The derivative of any of embodiments 1-34, wherein Xaa₃₁ is Lys.36. The derivative of any of embodiments 1-34, wherein Xaa₃₁ is Trp.37. The derivative of any of embodiments 1-36, wherein Xaa₃₃ is Val.38. The derivative of any of embodiments 1-37, wherein Xaa₃₄ is Arg.39. The derivative of any of embodiments 1-38, wherein Xaa₃₅ is Gly.40. The derivative of any of embodiments 1-39, wherein Xaa₃₆ is Arg orLys.41. The derivative of any of embodiments 1-40, wherein Xaa₃₆ is Arg.42. The derivative of any of embodiments 1-40, wherein Xaa₃₆ is Lys.43. The derivative of any of embodiments 1-42, wherein Xaa₃₇ is Gly.44. The derivative of any of embodiments 1-43, wherein Xaa₃₈ is Gly,Ala, Glu, Pro, or Lys.45. The derivative of any of embodiments 1-44, wherein Xaa₃₈ is Gly.46. The derivative of any of embodiments 1-44, wherein Xaa₃₈ is Ala.47. The derivative of any of embodiments 1-44, wherein Xaa₃₈ is Glu.48. The derivative of any of embodiments 1-44, wherein Xaa₃₈ is Pro.49. The derivative of any of embodiments 1-44, wherein Xaa₃₈ is Lys.50. The derivative of any of embodiments 1-49, wherein Xaa₃₉ is Ser,Gly, Ala, Glu, or Pro.51. The derivative of any of embodiments 1-50, wherein Xaa₃₉ is Ser.52. The derivative of any of embodiments 1-50, wherein Xaa₃₉ is Gly.53. The derivative of any of embodiments 1-50, wherein Xaa₃₉ is Ala.54. The derivative of any of embodiments 1-50, wherein Xaa₃₉ is Glu.55. The derivative of any of embodiments 1-50, wherein Xaa₃₉ is Pro.56. The derivative of any of embodiments 1-55, wherein Xaa₄₀ is Ser,Gly, Ala, Glu, or Pro.57. The derivative of any of embodiments 1-56, wherein Xaa₄₀ is Ser.58. The derivative of any of embodiments 1-56, wherein Xaa₄₀ is Gly.59. The derivative of any of embodiments 1-56, wherein Xaa₄₀ is Ala.60. The derivative of any of embodiments 1-56, wherein Xaa₄₀ is Glu.62. The derivative of any of embodiments 1-56, wherein Xaa₄₀ is Pro.63. The derivative of any of embodiments 1-62, wherein Xaa₄₁ is Ser,Gly, Ala, Glu, or Pro.64. The derivative of any of embodiments 1-63, wherein Xaa₄₁ is Ser.65. The derivative of any of embodiments 1-63, wherein Xaa₄₁ is Gly.66. The derivative of any of embodiments 1-63, wherein Xaa₄₁ is Ala.67. The derivative of any of embodiments 1-63, wherein Xaa₄₁ is Glu.68. The derivative of any of embodiments 1-63, wherein Xaa₄₁ is Pro.69. The derivative of any of embodiments 1-68, wherein the GLP-1 likepeptide is a peptide of Formula I.70. The derivative of any of embodiments 1-69, wherein in Formula I Xaa₇is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid,D-histidine, desamino-histidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine; Xaa₈ is Ala, Gly, Ser,Aib, (1-aminocyclopropyl) carboxylic acid, or (1-aminocyclobutyl)carboxylic acid; Xaa₁₂ is Phe; Xaa₁₆ is Val or Leu; Xaa₁₈ is Ser, Arg,or Lys; Xaa₁₉ is Tyr or Gln; Xaa₂₀ is Leu or Met; Xaa₂₂ is Gly or Glu;Xaa₂₃ is Gln, Glu, Lys, or Arg; Xaa₂₅ is Ala or Val; Xaa₂₆ is Arg orLys; Xaa₂₇ is Glu, Lys, or Leu; Xaa₃₀ is Ala or Glu; Xaa₃₁ is Trp, Lys,or His; Xaa₃₃ is Val, Lys, or Arg; Xaa₃₄ is Lys, Arg, or Asn; Xaa₃₅ isGly; Xaa₃₆ is Arg, Lys, or Gly; Xaa₃₇ is Gly or Pro; Xaa₃₈ is Gly, Ala,Glu, Pro, or Lys; Xaa₃₉ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₀ is Ser,Gly, Ala, Glu, or Pro; Xaa₄₁ is Ser, Gly, Ala, Glu, or Pro; and Xaa₄₂ isLys.71. The derivative of any of embodiments 1-70, wherein in Formula I Xaa₇is L-histidine, desamino-histidine, Xaa₈ is Aib; Xaa₁₂ is Phe; Xaa₁₆ isVal; Xaa₁₈ is Ser or Lys; Xaa₁₉ is Tyr; Xaa₂₀ is Leu; Xaa₂₂ is Glu;Xaa₂₃ is Gln or Lys; Xaa₂₅ is Ala; Xaa₂₆ is Arg; Xaa₂₇ is Glu or Lys;Xaa₃₀ is Ala; Xaa₃₁ is Trp or Lys; Xaa₃₃ is Val; Xaa₃₄ is Arg; Xaa₃₅ isGly; Xaa₃₆ is Arg or Lys; Xaa₃₇ is Gly; Xaa₃₈ is Gly, Ala, Glu, Pro, orLys; Xaa₃₉ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₀ is Ser, Gly, Ala, Glu,or Pro; Xaa₄₁ is Ser, Gly, Ala, Glu, or Pro; and Xaa₄₂ is Lys.72. The derivative of any of embodiments 1-71, wherein the GLP-1 likepeptide has a maximum of 12 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).73. The derivative of any of embodiments 1-72, wherein the GLP-1 likepeptide has a maximum of 11 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).74. The derivative of any of embodiments 1-73, wherein the GLP-1 likepeptide has a maximum of 10 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).75. The derivative of any of embodiments 1-74, wherein the GLP-1 likepeptide has a maximum of 9 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).76. The derivative of any of embodiments 1-75, wherein the GLP-1 likepeptide has a maximum of 8 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).77. The derivative of any of embodiments 1-76, wherein the GLP-1 likepeptide has a maximum of 7 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).78. The derivative of any of embodiments 1-77, wherein the GLP-1 likepeptide has a maximum of 6 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).79. The derivative of any of embodiments 1-78, wherein the GLP-1 likepeptide has a maximum of 5 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).80. The derivative of any of embodiments 1-79, wherein the GLP-1 likepeptide has a minimum of 5 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).81. The derivative of any of embodiments 1-80, wherein the GLP-1 likepeptide has a minimum of 6 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).82. The derivative of any of embodiments 1-81, wherein the GLP-1 likepeptide has a minimum of 7 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).83. The derivative of any of embodiments 1-82, wherein the GLP-1 likepeptide has a minimum of 8 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).84. The derivative of any of embodiments 1-83, wherein the GLP-1 likepeptide has a minimum of 9 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).85. The derivative of any of embodiments 1-84, wherein the GLP-1 likepeptide has a minimum of 10 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).86. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 5 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).87. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 6 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).88. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 7 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).89. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 8 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).90. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 9 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).91. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has 10 amino acid changes, when compared with GLP-1(7-37) (SEQID NO: 1).92. The derivative of any of embodiments 1-91, wherein the GLP-1 likepeptide is selected from the following analogues of GLP-1 (7-37) (SEQ IDNO: 1): i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ IDNO: 2); ii) (8Aib, 22E, 26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ IDNO: 3); iii) (8Aib, 22E, 26R, 34R, 38K, 39G, 40G, 41S, 42K) (SEQ ID NO:4); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO:5); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO:6); vi) (8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO:7); vii) (7Imp, 8Aib, 22E, 26R, 34R, 38K, 39G, 40G, 41S, 42K) (SEQ IDNO: 8); iix) (8Aib, 22E, 26R, 34R, 36K, 38A, 39E, 40S, 41P, 42K) (SEQ IDNO: 9); ix) (8Aib, 22E, 26R, 34R, 36K, 38E, 39G, 40P, 41A, 42K) (SEQ IDNO: 10); x) (8Aib, 22E, 26R, 34R, 36K, 38P, 39A, 40S, 41E, 42K) (SEQ IDNO: 11); xi) (8Aib, 22E, 26R, 34R, 38K, 39P, 40E, 41G, 42K) (SEQ ID NO:12); xii) (8Aib, 22E, 26R, 34R, 38K, 39S, 40A, 41E, 42K) (SEQ ID NO:13); and xiii) (8Aib, 22E, 26R, 34R, 38K, 39S, 40P, 41E, 42K) (SEQ IDNO: 14).93 The derivative of any of embodiments 1-92, wherein each of the firstand the second protracting moiety is Chem. 1.94. The derivative of any of embodiments 1-92, wherein each of the firstand the second protracting moiety is Chem. 1a.95. The derivative of any of embodiments 1-92, wherein each of the firstand the second protracting moiety is Chem. 1b.96. The derivative of any of embodiments 1-95, wherein each of the firstand the second protracting moiety is attached to the first and thesecond K residue, respectively, optionally via a first and a secondlinker, respectively.97. The derivative of embodiment 96, wherein each of the first and thesecond protracting moiety is attached to the first and the second Kresidue, respectively, via a first and a second linker, respectively.98. The derivative of any of embodiments 96-97, wherein the first andthe second linker each incorporates an *—NH or *—N group, and a *—COgroup.99. The derivative of any of embodiments 96-98, wherein each of thefirst and the second linker comprises an element_1 of formula Chem. 2:

100. The derivative of any of embodiments 96-99, wherein each of thefirst and the second linker incorporates one element_1 of formula Chem.2.101. The derivative of any of embodiments 99-100, wherein Chem. 2represents a gGlu residue.102. The derivative of any of embodiments 99-101, wherein element_1 isan L-gGlu residue.103. The derivative of any of embodiments 96-102, wherein each of thefirst and the second linker comprises an element_2 of formula Chem. 3:

wherein k is an integer in the range of 1-5, and n is an integer in therange of 1-5.104. The derivative of embodiment 103, wherein each of the first and thesecond linker comprises at least one element_2 of formula Chem. 3.105. The derivative of any of embodiments 103-104, wherein each of thefirst and the second linker comprises at least two elements_2 of formulaChem. 3.106. The derivative of any of embodiments 103-105, wherein each of thefirst and the second linker comprises two elements_2 of formula Chem. 3.107. The derivative of any of embodiments 103-106, wherein each of thefirst and the second linker incorporates two elements_2 of formula Chem.3.108. The derivative of any of embodiments 103-107, wherein each of thefirst and the second linker comprises four elements_2 of formula Chem.3.109. The derivative of any of embodiments 103-108, wherein each of thefirst and the second linker incorporates four elements_2 of formulaChem. 3.110. The derivative of any of embodiments 103-109, wherein each of thefirst and the second linker comprises five elements_2 of formula Chem.3.111. The derivative of any of embodiments 103-110, wherein each of thefirst and the second linker incorporates five elements_2 of formulaChem. 3.112. The derivative of any of embodiments 103-111, wherein each of thefirst and the second linker comprises six elements_2 of formula Chem. 3.113. The derivative of any of embodiments 103-112, wherein each of thefirst and the second linker incorporates six elements_2 of formula Chem.3.114. The derivative of any of embodiments 103-113, wherein k=1 and n=1.115. The derivative of any of embodiments 103-114, wherein Chem. 3represents OEG.116. The derivative of any of embodiments 103-104, wherein each of thefirst and the second linker comprises one element_2 of formula Chem. 3.117. The derivative of any of embodiments 103-104 and 116, wherein eachof the first and the second linker incorporates one element_2 of formulaChem. 3.118. The derivative of any of embodiments 116-117, wherein k=3 and n=2.119. The derivative of any of embodiments 116-118, wherein Chem. 3represents dPEG4.120. The derivative of any of embodiments 96-119, wherein each of thefirst and the second linker comprises an element_3 of formula Chem. 4:

121. The derivative of any of embodiments 96-120, wherein each of thefirst and second linker each incorporates one element_3 of formula Chem.4.122. The derivative of any of embodiments 120-121, wherein Chem. 4represents Trx.123. The derivative of any of embodiments 96-122, wherein each of thefirst and the second linker comprises an element_4 of formula Chem. 5:

*—NH—(CH₂)_(q)—CH[(CH₂)_(w)—NH₂]—CO—*,  Chem. 5:

wherein q is an integer in the range of 0-5, and w is an integer in therange of 0-5, with the provisos that when w is 0 q is an integer in therange of 1-5, and when q is 0 w is an integer in the range of 1-5.

124. The derivative of embodiment 123, wherein each of the first and thesecond linker comprises at least one element_4 of formula Chem. 5.125. The derivative of any of embodiments 123-124, wherein each of thefirst and the second linker comprises at least two elements_4 of formulaChem. 5.126. The derivative of any of embodiments 123-125, wherein each of thefirst and the second linker comprises two elements_4 of formula Chem. 5.127. The derivative of any of embodiments 123-126, wherein each of thefirst and the second linker incorporates two elements_4 of formula Chem.5.128. The derivative of any of embodiments 123-127, wherein q is 4 and wis 0.129. The derivative of any of embodiments 123-127, wherein w is 4 and qis 0.130. The derivative of any of embodiments 123-129, wherein Chem. 5represents an eps-Lys residue.131. The derivative of any of embodiments 123-130, wherein element_4 isan L-eps-Lys residue.132. The derivative of any of embodiments 96-131, wherein each of thefirst and the second linker comprises an element_5 of formula Chem. 6:

wherein y is 1 or 2, z is 1 or 2, p is 0 or 1, and X designates a carbonatom or an oxygen atom.133. The derivative of embodiment 132, wherein each of the first and thesecond linker incorporates one element_5 of formula Chem. 6.134. The derivative of any of embodiments 132-133, wherein y is 2, z is2, p is 1, and X represents an oxygen atom.135. The derivative of embodiment 134, wherein Chem. 6 represents aTotaGlyc residue or formula Chem. 7:

136. The derivative of any of embodiments 132-133, wherein y is 2, z is2, p is 0, and X represents a carbon atom.137. The derivative of embodiment 136, wherein Chem. 6 represents aTtdSuc.residue of formula Chem. 8:

138. The derivative of any of embodiments 132-133, wherein y is 1, z is1, p is 0, and X represents a carbon atom.139. The derivative of embodiment 138, wherein Chem. 6 represents aDooaSuc residue of formula Chem. 9:

140. The derivative of any of embodiments 96-139, wherein each of thefirst and the second linker comprises an element_6 of formula Chem. 10:

141. The derivative of any of embodiments 96-140, wherein each of thefirst and the second linker incorporates one element_6 of formula Chem.10.142. The derivative of any of embodiments 140-141, wherein Chem. 10represents an Mb residue.144. The derivative of any of embodiments 1-142 which comprises at leastone of the linker elements element_1, element_2, element_3, element_4,element_5, and element_6.145. The derivative of embodiment 144, wherein each of the linkerelements is defined as in any of embodiments 99-142.146. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and two elements_2 of formula Chem.3 wherein k=1 and n=1, interconnected via amide bonds and in thesequence indicated.147. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and four elements_2 of formulaChem. 3 wherein k=1 and n=1, interconnected via amide bonds and in thesequence indicated.148. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and six elements_2 of formula Chem.3 wherein k=1 and n=1, interconnected via amide bonds and in thesequence indicated.149. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and one element_2 of formula Chem.3 wherein k=3 and n=2, interconnected via amide bonds and in thesequence indicated.150. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and two elements_4 of formula Chem.5 wherein q=4 and w=0 (or w=4 and q=0), interconnected via amide bondsand in the sequence indicated.151. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and one element_5 of formula Chem.9, interconnected via amide bonds and in the sequence indicated.152. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_1 of formula Chem. 2and two elements_4 of formula Chem. 5 wherein q=4 and w=0 (or w=4 andq=0), interconnected via amide bonds and in the sequence indicated.153. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_1 of formula Chem. 2and four elements_2 of formula Chem. 3 wherein k=1 and n=1,interconnected via amide bonds and in the sequence indicated.154. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_1 of formula Chem. 2and one element_5 of formula Chem. 7, interconnected via amide bonds andin the sequence indicated.155. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of two elements_4 of formula Chem.5 and four elements_2 of formula Chem. 3 wherein k=1 and n=1,interconnected via amide bonds and in the sequence indicated.156. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of two elements_4 of formula Chem.5 and five elements_2 of formula Chem. 3 wherein k=1 and n=1,interconnected via amide bonds and in the sequence indicated.157. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of two elements_4 of formula Chem.5 and six elements_2 of formula Chem. 3 wherein k=1 and n=1,interconnected via amide bonds and in the sequence indicated.158. The derivative of any of embodiments 1-145, wherein each of thefirst and the second linker consists of one element_6 of formula Chem.10, one element_1 of formula Chem. 2, and one element_5 of formula Chem.8, interconnected via amide bonds and in the sequence indicated.159. The derivative of any of embodiments 1-158, wherein the CO—* groupof each of the first and second protracting moieties, such as Chem. 1,Chem. 1a, or Chem. 1b, is attached to the epsilon amino group of thefirst and second K residue, respectively, optionally via a first and asecond linker, respectively.160. The derivative of any of embodiments 1-159, wherein the CO—* groupof each of the first and second protracting moieties, such as Chem. 1,Chem. 1a, or Chem. 1b, is attached to the epsilon amino group of thefirst and second K residue, respectively, via a first and a secondlinker, respectively.161. The derivative of any of embodiments 1-160, wherein each of thefirst and the second protracting moiety is attached to the epsilon aminogroup of the first and the second K-residue, respectively, under theformation of an amide bond, optionally via a first and a second linker,respectively, which is connected via amide bonds to the first and thesecond protracting moiety as well as to the first and the second Kresidue.162. The derivative of any of embodiments 1-161, wherein each of thefirst and the second protracting moiety is attached to the epsilon aminogroup of the first and the second K-residue, respectively, under theformation of an amide bond, via a first and a second linker,respectively, which is connected via amide bonds to the first and thesecond protracting moiety as well as to the first and the second Kresidue.163. The derivative of any of embodiments 1-162, wherein the CO—* groupof each of the first and the second protracting moieties is attached toan *—NH or *—N group of a first and a second linker, respectively, and a*—CO group of each of the first and the second linker is attached to theepsilon amino group of the first and the second K-residue, respectively.164. The derivative of any of embodiments 1-163, in the form of an acidor basic salt.165. The derivative of any of embodiments 1-164 in the form of an acidsalt.166. The derivative of any of embodiments 1-165 in the form of anacetate salt.167. The derivative of any of embodiments 1-163 in the form of a basicsalt168. The derivative of any of embodiments 1-167 in the form of a sodiumor potassium salt.169. The derivative of any of embodiments 1-168 in the form of a sodiumsalt.170. The derivative of any of embodiments 1-169 in the form of apotassium salt.171. The derivative of any of embodiments 1-170 which is a GLP-1receptor agonist.172. The derivative of any of embodiments 1-171, which is a full GLP-1receptor agonist.173. The derivative of any of embodiments 1-172, which is biologicallyactive in vitro.174. The derivative of any of embodiments 1-173, which is potent invitro.175. The derivative of any of embodiments 1-174, which is capable ofactivating the human GLP-1 receptor.176. The derivative of any of embodiments 1-175 which is capable ofactivating the human GLP-1 receptor in an assay with whole cellsexpressing the human GLP-1 receptor, wherein the assay is performed inthe absence of HSA (0% HSA), and/or in the presence of HSA (1% HSA)),preferably in the absence of HSA.177. The derivative of any of embodiments 1-176, where the response ofthe human GLP-1 receptor is measured in a reporter gene assay, such asthe assay of Example 29.178. The derivative of any of embodiments 1-177, wherein the biologicalactivity, or potency, in vitro is determined essentially as described inExample 29.179. The derivative of any of embodiments 1-178, which has an in vitropotency corresponding to an EC₅₀ of 400 pM or below.180. The derivative of any of embodiments 1-179, which has an in vitropotency corresponding to an EC₅₀ of 300 pM or below.181. The derivative of any of embodiments 1-180, which has an in vitropotency corresponding to an EC₅₀ of 100 pM or below.182. The derivative of any of embodiments 1-181, which has an in vitropotency corresponding to an EC₅₀ of 75 pM or below.183. The derivative of any of embodiments 1-182, which has an in vitropotency corresponding to an EC₅₀ of 55 pM or below.184. The derivative of any of embodiments 1-183, which has an in vitropotency corresponding to an EC₅₀ of 40 pM or below.185. The derivative of any of embodiments 1-184, which has an in vitropotency corresponding to an EC₅₀ of 25 pM or below.186. The derivative of any of embodiments 1-183, which has an in vitropotency corresponding to an EC₅₀ of 15 pM or below.187. The derivative of any of embodiments 1-183, which has an in vitropotency corresponding to an EC₅₀ of 10 pM or below.188. The derivative of any of embodiments 179-187, wherein the EC₅₀ isdetermined essentially as described in Example 29.189. The derivative of any of embodiments 1-188, which has an in vitropotency corresponding to an EC₅₀ of less than 50 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.190. The derivative of any of embodiments 1-189, which has an in vitropotency corresponding to an EC₅₀ of less than 40 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.191. The derivative of any of embodiments 1-190, which has an in vitropotency corresponding to an EC₅₀ of less than 30 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.192. The derivative of any of embodiments 1-191, which has an in vitropotency corresponding to an EC₅₀ of less than 20 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.193. The derivative of any of embodiments 1-192, which has an in vitropotency corresponding to an EC₅₀ of less than 8 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.194. The derivative of any of embodiments 1-193, which has an in vitropotency corresponding to an EC₅₀ of less than 5 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.195. The derivative of any of embodiments 1-194, which has an in vitropotency corresponding to an EC₅₀ of less than 3.5 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.196. The derivative of any of embodiments 1-195, which has an in vitropotency corresponding to an EC₅₀ of less than 2 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.197. The derivative of any of embodiments 189-196, wherein the EC₅₀ isdetermined essentially as described in Example 29.198. The derivative of any of embodiments 1-197, which is capable ofbinding to the GLP-1 receptor.199. The derivative of any of embodiments 1-198, which is capable ofbinding to the GLP-1 receptor at a low concentration of HSA (max. 0.001%final assay concentration).200. The derivative of any of embodiments 1-199, which is capable ofbinding to the GLP-1 receptor at a high concentration of HSA (2.0% finalassay concentration).201. The derivative of any of embodiments 1-200, wherein the binding tothe human GLP-1 receptor is measured in a competitive binding assay,such as the assay of Example 30.202. The derivative of any of embodiments 1-201, wherein the binding tothe human GLP-1 receptor in vitro is determined essentially as describedin Example 30.203. The derivative of any of embodiments 1-202, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 5.0 nM or below.204. The derivative of any of embodiments 1-203, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 4.0 nM or below.205. The derivative of any of embodiments 1-204, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 3.0 nM or below.206. The derivative of any of embodiments 1-205, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 2.0 nM or below.207. The derivative of any of embodiments 1-206, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 1.0 nM or below.208. The derivative of any of embodiments 1-207, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 0.8 nM or below.209. The derivative of any of embodiments 203-208, wherein the IC₅₀ isdetermined essentially as described in Example 30, in a reaction withmax. 0.001% HSA (final assay concentration).210. The derivative of any of embodiments 1-209, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 8 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.211. The derivative of any of embodiments 1-210, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 6 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.212. The derivative of any of embodiments 1-211, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 4.5 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.213. The derivative of any of embodiments 1-212, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 3 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.214. The derivative of any of embodiments 1-213, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 2 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.215. The derivative of any of embodiments 1-214, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 1.5 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.216. The derivative of any of embodiments 1-215, which at a lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 1 time the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.217. The derivative of any of embodiments 210-216, wherein the IC₅₀ isdetermined essentially as described in Example 30, in a reaction withmax. 0.001% HSA (final assay concentration).218. The derivative of any of embodiments 1-217, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 950 nM or below.219. The derivative of any of embodiments 1-218, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 650 nM or below.220. The derivative of any of embodiments 1-219, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 550 nM or below.221. The derivative of any of embodiments 1-220, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 500 nM or below.222. The derivative of any of embodiments 1-221, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 400 nM or below.223. The derivative of any of embodiments 1-222, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 300 nM or below.224. The derivative of any of embodiments 1-223, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 200 nM or below.225. The derivative of any of embodiments 1-224, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 150 nM or below.226. The derivative of any of embodiments 218-225, wherein the IC₅₀ isdetermined essentially as described in Example 30, in a reaction with2.0% HSA (final assay concentration).227. The derivative of any of embodiments 1-226, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 3 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.228. The derivative of any of embodiments 1-227, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 2 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.229. The derivative of any of embodiments 1-228, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 1.5 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.230. The derivative of any of embodiments 1-229, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 1 time the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.231. The derivative of any of embodiments 1-230, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 0.8 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.232. The derivative of any of embodiments 1-231, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 0.35 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.233. The derivative of any of embodiments 227-232, wherein the IC₅₀ isdetermined essentially as described in Example 30, in a reaction with2.0% HSA (final assay concentration).234. The derivative of any of embodiments 1-233, which has improvedpharmacokinetic properties.235. The derivative of any of embodiments 1-234, which has an increasedhalf-life and/or a decreased clearance.236. The derivative of any of embodiments 1-235, which is suitable foronce-monthly administration.237. The derivative of any of embodiments 1-236, for s.c.administration.238. The derivative of any of embodiments 1-237, wherein the derivativeis tested in vivo in pharmacokinetic (PK) studies.239. The derivative of any of embodiments 1-238, wherein the derivativeis tested in any suitable animal model, such as mouse, rat, monkey, dog,or pig.240. The derivative of any of embodiments 1-239, which is compared withsemaglutide.241. The derivative of any of embodiments 1-240, which has an improvedterminal half-life (T½) in vivo in minipigs after i.v. administration ascompared to semaglutide.242. The derivative of any of embodiments 1-241, wherein the terminalhalf-life is determined in vivo in minipigs after i.v. administrationusing any suitable study protocol, such as the one described in Example31.243. The derivative of any of embodiments 1-242, wherein the terminalhalf-life is determined in vivo in minipigs after i.v. administration,essentially as described in Example 31.244. The derivative of any of embodiments 1-243, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least90 hours.245. The derivative of any of embodiments 1-244, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least100 hours.246. The derivative of any of embodiments 1-245, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least125 hours.247. The derivative of any of embodiments 1-246, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least140 hours.248. The derivative of any of embodiments 1-247, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least1.5 times the terminal half-life of semaglutide, determined in the sameway.249. The derivative of any of embodiments 1-248, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2 times the terminal half-life of semaglutide, determined in the sameway.250. The derivative of any of embodiments 1-249, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2.3 times the terminal half-life of semaglutide, determined in the sameway.251. The derivative of any of embodiments 1-250, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2.6 times the terminal half-life of semaglutide, determined in the sameway.252. The derivative of any of embodiments 1-251, which is potent invivo.253. The derivative of any of embodiments 1-252, which is potent in vivowhen determined in any suitable animal model, such as mouse or pig.254. The derivative of any of embodiments 1-253, wherein the animalmodel is db/db mouse.255. The derivative of any of embodiments 1-254, wherein the bloodglucose lowering effect is determined.256. The derivative of any of embodiments 1-255, wherein the body weightlowering effect is determined.257. The derivative of any of embodiments 1-256, wherein blood glucoselowering effect and/or body weight lowering effect is determined in vivoin db/db mouse using any suitable study protocol and methodology, e.g.as described in Example 32.258. The derivative of any of embodiments 1-257, wherein the bloodglucose lowering effect and/or the body weight lowering effect isdetermined in vivo in db/db mouse, essentially as described in Example32.259. The derivative of any of embodiments 1-258, which has the effect invivo of reducing blood glucose after 48 hours, determined in asingle-dose study in a db/db mouse model.260. The derivative of any of embodiments 1-259, wherein the bloodglucose is reduced by at least 15%, as compared to the blood glucoselevel before administration of the derivative.261. The derivative of any of embodiments 1-260, wherein the bloodglucose is reduced by at least 25%, as compared to the blood glucoselevel before administration of the derivative.262. The derivative of any of embodiments 1-261 wherein the bloodglucose is reduced by at least 35%, as compared to the blood glucoselevel before administration of the derivative.263. The derivative of any of embodiments 1-262, wherein the bloodglucose is reduced by at least 50%, as compared to the blood glucoselevel before administration of the derivative.264. The derivative of any of embodiments 1-263, which has the effect invivo of reducing blood glucose after 72 hours, determined in asingle-dose study in a db/db mouse model.265. The derivative of any of embodiments 1-264, which has the effect invivo of reducing blood glucose after 96 hours, determined in asingle-dose study in a db/db mouse model.266. The derivative of any of embodiments 1-265, wherein the bloodglucose is reduced by at least 3%, as compared to the blood glucoselevel before administration of the derivative.267. The derivative of any of embodiments 1-266, wherein the bloodglucose is reduced by at least 5%, as compared to the blood glucoselevel before administration of the derivative.268. The derivative of any of embodiments 1-267, wherein the bloodglucose is reduced by at least 10%, as compared to the blood glucoselevel before administration of the derivative.269. The derivative of any of embodiments 1-268, wherein the bloodglucose is reduced by at least 15%, as compared to the blood glucoselevel before administration of the derivative.270. The derivative of any of embodiments 1-269, wherein the bloodglucose is reduced by at least 20%, as compared to the blood glucoselevel before administration of the derivative.271. The derivative of any of embodiments 1-270, wherein the bloodglucose is reduced by at least 25%, as compared to the blood glucoselevel before administration of the derivative.272. The derivative of any of embodiments 1-271, which has the effect invivo of reducing body weight after 48 hours, determined in a single-dosestudy in a db/db mouse model.273. The derivative of any of embodiments 1-272, wherein the body weightis reduced by at least 3%, as compared to the body weight beforeadministration of the derivative.274. The derivative of any of embodiments 1-273, wherein the body weightis reduced by at least 4%, as compared to the body weight beforeadministration of the derivative.275. The derivative of any of embodiments 1-274, wherein the body weightis reduced by at least 5%, as compared to the body weight beforeadministration of the derivative.276. The derivative of any of embodiments 1-275, wherein the body weightis reduced by at least 6%, as compared to the body weight beforeadministration of the derivative.277. The derivative of any of embodiments 1-276, which has the effect invivo of reduced body weight after 72 hours, determined in a single-dosestudy in a db/db mouse model.278. The derivative of any of embodiments 1-277 which has the effect invivo of reducing body weight after 96 hours, determined in a single-dosestudy in a db/db mouse model.279. The derivative of any of embodiments 1-278, wherein the body weightis reduced by at least 1%, as compared to the body weight beforeadministration of the derivative.280. The derivative of any of embodiments 1-279, wherein the body weightis reduced by at least 2%, as compared to the body weight beforeadministration of the derivative.281. The derivative of any of embodiments 1-280, wherein the body weightis reduced by at least 3%, as compared to the body weight beforeadministration of the derivative.282. The derivative of any of embodiments 1-281, wherein the body weightis reduced by at least 4%, as compared to the body weight beforeadministration of the derivative.283. The derivative of any of embodiments 1-282, wherein the animalmodel is pig.284. The derivative of any of embodiments 1-283, wherein the animalmodel is LYD pig.285. The derivative of any of embodiments 1-284, wherein the reductionin food intake is determined in an in vivo pharmacodynamic (PD) study.286. The derivative of any of embodiments 1-285, wherein the reductionin food intake is determined in vivo in pig using any suitable studyprotocol and methodology, e.g. as described in Example 33.287. The derivative of any of embodiments 1-286, wherein the reductionin food intake is determined in vivo in pig using any suitable studyprotocol and methodology, essentially as described in Example 33.288. The derivative of any of embodiments 1-287, which has the effect invivo of reducing food intake during a first period of 24 hours (0-24hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.289. The derivative of any of embodiments 1-288, which has the effect invivo of reducing food intake during a second period of 24 hours (24-48hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.290. The derivative of any of embodiments 1-289, which has the effect invivo of reducing food intake during a third period of 24 hours (48-72hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.291. The derivative of any of embodiments 1-290, which has the effect invivo of reducing food intake during a fourth period of 24 hours (72-96hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.292. A GLP-1 derivative selected from the following: Chem. 21, Chem. 22,Chem. 23, Chem. 24, Chem. 25, Chem. 26, Chem. 27, Chem. 28, Chem. 29,Chem. 30, Chem. 31, Chem. 32, Chem. 33, Chem. 34, Chem. 35, Chem. 36,Chem. 37, Chem. 38, Chem. 39, Chem. 40, Chem. 41, Chem. 42, Chem. 43,Chem. 44, Chem. 45, Chem. 46, Chem. 47, and Chem. 48; or apharmaceutically acceptable salt, amide, or ester thereof.293. A GLP-1 derivative selected from the chemical structures shown inany of Examples 1-28; or a pharmaceutically acceptable salt, amide, orester thereof.294. A GLP-1 derivative selected from the GLP-1 derivative names shownin any of Examples 1-28; or a pharmaceutically acceptable salt, amide,or ester thereof.295. The derivative of any of embodiments 292-294, which is a derivativeaccording to any of embodiments 1-291.296. An intermediate product in the form of a GLP-1 analogue, whichcomprises the following amino acid changes when compared to GLP-1 (7-37)(SEQ ID NO: 1):i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii) (8Aib, 22E,26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E, 26R, 34R, 38K,39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S,42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K); vi) (8Aib,18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K); vii) (7Imp, 8Aib, 22E,26R, 34R, 38K, 39G, 40G, 41S, 42K); iix) (8Aib, 22E, 26R, 34R, 36K, 38A,39E, 40S, 41P, 42K); ix) (8Aib, 22E, 26R, 34R, 36K, 38E, 39G, 40P, 41A,42K); x) (8Aib, 22E, 26R, 34R, 36K, 38P, 39A, 40S, 41E, 42K); xi) (8Aib,22E, 26R, 34R, 38K, 39P, 40E, 41G, 42K) (SEQ ID NO: 12); xii) (8Aib,22E, 26R, 34R, 38K, 39S, 40A, 41E, 42K); or xiii) (8Aib, 22E, 26R, 34R,38K, 39S, 40P, 41E, 42K).297. An intermediate product in the form of a GLP-1 analogue, selectedfrom the following analogues of GLP-1 (7-37) (SEQ ID NO: 1):i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO: 2);ii) (8Aib, 22E, 26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO: 3);iii) (8Aib, 22E, 26R, 34R, 38K, 39G, 40G, 41S, 42K) (SEQ ID NO: 4); iv(8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO: 5); v)(8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO: 6); vi)(8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K) (SEQ ID NO: 8), vii)(7Imp, 8Aib, 22E, 26R, 34R, 38K, 39G, 40G, 41S, 42K) (SEQ ID NO: 8);iix) (8Aib, 22E, 26R, 34R, 36K, 38A, 39E, 40S, 41P, 42K) (SEQ ID NO: 9);ix) (8Aib, 22E, 26R, 34R, 36K, 38E, 39G, 40P, 41A, 42K) (SEQ ID NO: 10);x) (8Aib, 22E, 26R, 34R, 36K, 38P, 39A, 40S, 41E, 42K) (SEQ ID NO: 11);xi) (8Aib, 22E, 26R, 34R, 38K, 39P, 40E, 41G, 42K) (SEQ ID NO: 12); xii)(8Aib, 22E, 26R, 34R, 38K, 39S, 40A, 41E, 42K) (SEQ ID NO: 13); andxiii) (8Aib, 22E, 26R, 34R, 38K, 39S, 40P, 41E, 42K) (SEQ ID NO: 14).298. A pharmaceutical composition comprising a derivative according toany of embodiments 1-295, or an analogue according to any of embodiments296-297, and a pharmaceutically acceptable excipient.299. A derivative according to any of embodiments 1-295, or an analogueaccording to any of embodiments 296-297, for use as a medicament.300. A derivative according to any of embodiments 1-295, or an analogueaccording to any of embodiments 296-297, for use in

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse.

301. Use of a derivative according to any of embodiments 1-208, or ananalogue according to any of embodiments 209-210, in the manufacture ofa medicament for

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse.

302. A method for

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse;

wherein a pharmaceutically active amount of a derivative according toany of embodiments 1-295, or an analogue according to any of embodiments296-297, is administered.

Additional Particular Embodiments

The following are additional particular embodiments of the invention:

1. A derivative of a GLP-1 like peptide of formula I:

Formula I: Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,wherein

Xaa₇ is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid,D-histidine, desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine;

Xaa₈ is Ala, Gly, Ser, Aib, (1-aminocyclopropyl) carboxylic acid, or(1-aminocyclobutyl) carboxylic acid;

Xaa₁₂ is Phe or Leu;

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Arg, Lys, Val, or Leu;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys, or Arg;

Xaa₂₅ is Ala or Val;

Xaa₂₆ is Arg or Lys;

Xaa₂₇ is Glu, Lys, or Leu;

Xaa₃₀ is Ala, Glu, or Arg;

Xaa₃₁ is Trp, Lys, or His;

Xaa₃₃ is Val, Lys, or Arg;

Xaa₃₄ is Lys, Arg, His, Asn, or Gln;

Xaa₃₅ is Gly or Ala;

Xaa₃₆ is Arg, Lys, or Gly;

Xaa₃₇ is Gly or Pro;

Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys;

Xaa₃₉ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₁ is Ser, Gly, Ala, Glu, or Pro; and

Xaa₄₂ is Lys;

with the proviso that at least one of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆,or Xaa₃₈ is Lys;

wherein

Lys at Xaa₄₂ is a first K residue, and a Lys at one of Xaa₁₈, Xaa₂₃,Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is a second K residue;

which derivative comprises a first and a second protracting moietyconnected to said first and second K residue, respectively, wherein thefirst and second protracting moiety is of formula Chem. 1:

HOOC—(CH₂)₁₈—CO—*;  Chem. 1:

or a pharmaceutically acceptable salt, amide, or ester thereof.2. The derivative of embodiment 1, wherein each of the first and thesecond protracting moiety is attached to the first and the second Kresidue, respectively, optionally via a first and a second linker,respectively.3. The derivative of embodiment 2, wherein the first and the secondlinker each incorporates an *—NH group, and a *—CO group.4. The derivative of any of embodiments 2-3, wherein each of the firstand the second linker comprises an element_1 of formula Chem. 2:

5. The derivative of embodiment 4, wherein each of the first and thesecond linker incorporates one element_1 of formula Chem. 2.6. The derivative of any of embodiments 4-5, wherein Chem. 2 representsa gGlu residue.7. The derivative of any of embodiments 4-6, wherein element_1 is anL-gGlu residue.8. The derivative of any of embodiments 2-7, wherein each of the firstand the second linker comprises an element_2 of formula Chem. 3:

wherein k is an integer in the range of 1-5, and n is an integer in therange of 1-5.9. The derivative of embodiment 8, wherein each of the first and thesecond linker comprises at least one element_2 of formula Chem. 3.10. The derivative of any of embodiments 8-9, wherein each of the firstand the second linker comprises at least two elements_2 of formula Chem.3.11. The derivative of any of embodiments 8-10, wherein each of the firstand the second linker comprises two elements_2 of formula Chem. 3.12. The derivative of any of embodiments 8-11, wherein each of the firstand the second linker incorporates two elements_2 of formula Chem. 3.13. The derivative of any of embodiments 8-12, wherein k=1 and n=1.14. The derivative of any of embodiments 8-13, wherein Chem. 3represents OEG.15. The derivative of any of embodiments 2-14, wherein each of the firstand the second linker comprises an element_3 of formula Chem. 4:

16. The derivative of any of embodiments 2-15, wherein each of the firstand second linker each incorporates one element_3 of formula Chem. 4.17. The derivative of any of embodiments 15-16, wherein Chem. 4represents Trx.18. The derivative of any of embodiments 2-17, wherein each of the firstand the second linker comprises an element_4 of formula Chem. 5:

*—NH—(CH₂)_(q)—CH[(CH₂)_(w)—NH₂]—CO—*,  Chem. 5:

wherein q is an integer in the range of 0-5, and w is an integer in therange of 0-5, with the provisos that when w is 0 q is an integer in therange of 1-5, and when q is 0 w is an integer in the range of 1-5.

19. The derivative of embodiment 18, wherein each of the first and thesecond linker comprises at least one element_4 of formula Chem. 5.20. The derivative of any of embodiments 18-19, wherein each of thefirst and the second linker comprises at least two elements_4 of formulaChem. 5.21. The derivative of any of embodiments 18-20, wherein each of thefirst and the second linker comprises two elements_4 of formula Chem. 5.22. The derivative of any of embodiments 18-21, wherein each of thefirst and the second linker incorporates two elements_4 of formula Chem.5.23. The derivative of any of embodiments 18-22, wherein q is 4 and w is0.24. The derivative of any of embodiments 18-22, wherein w is 4 and q is0.25. The derivative of any of embodiments 18-24, wherein Chem. 5represents an eps-Lys residue.25a. The derivative of any of embodiments 18-25, wherein element_4 is anL-eps-Lys residue.26. The derivative of any of embodiments 2-25a, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and two elements_2 of formula Chem.3 wherein k=1 and n=1, interconnected via amide bonds and in thesequence indicated.27. The derivative of any of embodiments 2-25a, wherein each of thefirst and the second linker consists of one element_3 of formula Chem.4, one element_1 of formula Chem. 2, and two elements_4 of formula Chem.5 wherein q=4 and w=0 (or w=4 and q=0), interconnected via amide bondsand in the sequence indicated.28. The derivative of any of embodiments 2-25a, wherein each of thefirst and the second linker consists of one element_1 of formula Chem. 2and two elements_4 of formula Chem. 5 wherein q=4 and w=0 (or w=4 andq=0), interconnected via amide bonds and in the sequence indicated.29. The derivative of any of embodiments 1-28, wherein the CO—* group ofChem. 1 of each of the first and second protracting moieties is attachedto the epsilon amino group of the first and second K residue,respectively, optionally via a first and a second linker, respectively.30. The derivative of any of embodiments 1-29, wherein each of the firstand the second protracting moiety is attached to the epsilon amino groupof the first and the second K-residue, respectively, under the formationof an amide bond, optionally via a first and a second linker,respectively, which is connected via amide bonds to the first and thesecond protracting moiety as well as to the first and the second Kresidue.31. The derivative of any of embodiments 1-30, wherein the CO—* group ofChem. 1 of each of the first and second protracting moieties is attachedto an *—NH group of a first and a second linker, respectively, and a*—CO group of each of the first and the second linker is attached to theepsilon amino group of the first and the second K-residue, respectively.31a. The derivative of any of embodiments 1-31, wherein one of Xaa₁₈,Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys.31b. The derivative of any of embodiments 1-31a, wherein only one ofXaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is Lys.32. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₁₈is the second K residue.33. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₂₃is the second K residue.34. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₂₇is the second K residue.35. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₃₁is the second K residue.36. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₃₆is the second K residue.37. The derivative of any of embodiments 1-31 b, wherein a Lys at Xaa₃₈is the second K residue.38. The derivative of any of embodiments 1-37, wherein Xaa₇ is His.39. The derivative of any of embodiments 1-38, wherein Xaa₈ is Aib.40. The derivative of any of embodiments 1-39, wherein Xaa₁₂ is Phe.41. The derivative of any of embodiments 1-40, wherein Xaa₁₆ is Val.42. The derivative of any of embodiments 1-41, wherein Xaa₁₈ is Ser orLys.43. The derivative of any of embodiments 1-42, wherein Xaa₁₈ is Ser.44. The derivative of any of embodiments 1-42, wherein Xaa₁₈ is Lys.45. The derivative of any of embodiments 1-44, wherein Xaa₁₉ is Tyr.46. The derivative of any of embodiments 1-45, wherein Xaa₂₀ is Leu.47. The derivative of any of embodiments 1-46, wherein Xaa₂₂ is Glu.48. The derivative of any of embodiments 1-47, wherein Xaa₂₃ is Gln orLys.49. The derivative of any of embodiments 1-48, wherein Xaa₂₃ is Gln.50. The derivative of any of embodiments 1-48, wherein Xaa₂₃ is Lys.51. The derivative of any of embodiments 1-50, wherein Xaa₂₅ is Ala.52. The derivative of any of embodiments 1-51, wherein Xaa₂₆ is Arg.53. The derivative of any of embodiments 1-52, wherein Xaa₂₇ is Glu orLys.54. The derivative of any of embodiments 1-53, wherein Xaa₂₇ is Glu.55. The derivative of any of embodiments 1-54, wherein Xaa₂₇ is Glu orLys.56. The derivative of any of embodiments 1-54, wherein Xaa₂₇ is Lys.57. The derivative of any of embodiments 1-56, wherein Xaa₃₀ is Ala.58. The derivative of any of embodiments 1-57, wherein Xaa₃₁ is Trp orLys.59. The derivative of any of embodiments 1-58, wherein Xaa₃₁ is Lys.60. The derivative of any of embodiments 1-58, wherein Xaa₃₁ is Trp.61. The derivative of any of embodiments 1-60, wherein Xaa₃₃ is Val.62. The derivative of any of embodiments 1-61, wherein Xaa₃₄ is Arg.63. The derivative of any of embodiments 1-62, wherein Xaa₃₅ is Gly.64. The derivative of any of embodiments 1-63, wherein Xaa₃₆ is Arg orLys.65. The derivative of any of embodiments 1-64, wherein Xaa₃₆ is Arg.66. The derivative of any of embodiments 1-64, wherein Xaa₃₆ is Lys.67. The derivative of any of embodiments 1-66, wherein Xaa₃₇ is Gly.68. The derivative of any of embodiments 1-70, wherein Xaa₃₇ is Lys.73. The derivative of any of embodiments 1-72, wherein Xaa₃₈ is Gly orLys.74. The derivative of any of embodiments 1-73, wherein Xaa₃₈ is Gly.75. The derivative of any of embodiments 1-73, wherein Xaa₃₈ is Lys.76. The derivative of any of embodiments 1-75, wherein Xaa₃₉ is Gly.77. The derivative of any of embodiments 1-76, wherein Xaa₄₀ is Gly.78. The derivative of any of embodiments 1-77, wherein Xaa₄₁ is Ser.79. The derivative of any of embodiments 1-78, wherein the GLP-1 likepeptide has a maximum of 12 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).80. The derivative of any of embodiments 1-79, wherein the GLP-1 likepeptide has a maximum of 11 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).81. The derivative of any of embodiments 1-80, wherein the GLP-1 likepeptide has a maximum of 10 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).82. The derivative of any of embodiments 1-81, wherein the GLP-1 likepeptide has a maximum of 9 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).83. The derivative of any of embodiments 1-82, wherein the GLP-1 likepeptide has a maximum of 8 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).84. The derivative of any of embodiments 1-83, wherein the GLP-1 likepeptide has a maximum of 7 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).85. The derivative of any of embodiments 1-84, wherein the GLP-1 likepeptide has a maximum of 6 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).86. The derivative of any of embodiments 1-85, wherein the GLP-1 likepeptide has a maximum of 5 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).87. The derivative of any of embodiments 1-86, wherein the GLP-1 likepeptide has a minimum of 5 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).88. The derivative of any of embodiments 1-87, wherein the GLP-1 likepeptide has a minimum of 6 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).89. The derivative of any of embodiments 1-88, wherein the GLP-1 likepeptide has a minimum of 7 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).90. The derivative of any of embodiments 1-89, wherein the GLP-1 likepeptide has a minimum of 8 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).91. The derivative of any of embodiments 1-90, wherein the GLP-1 likepeptide has a minimum of 9 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).92. The derivative of any of embodiments 1-91, wherein the GLP-1 likepeptide has a minimum of 10 amino acid changes, when compared withGLP-1(7-37) (SEQ ID NO: 1).93. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 5 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).94. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 6 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).95. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 7 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).96. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 8 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).97. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 9 amino acid changes, when compared with GLP-1(7-37) (SEQ IDNO: 1).98. The derivative of any of embodiments 1-92, wherein the GLP-1 likepeptide has 10 amino acid changes, when compared with GLP-1(7-37) (SEQID NO: 1).99. The derivative of any of embodiments 1-98, wherein the GLP-1 likepeptide comprises at least two Lys residues.99a. The derivative of any of embodiments 1-99, wherein the GLP-1 likepeptide comprises two Lys residues.99b. The derivative of any of embodiments 1-99a, wherein the GLP-1 likepeptide has two Lys residues.99c. The derivative of any of embodiments 1-99b, wherein the GLP-1 likepeptide has only two Lys residues.100. The derivative of any of embodiments 1-99c, wherein the GLP-1 likepeptide is selected from the following analogues of GLP-1 (7-37) (SEQ IDNO: 1): i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii)(8Aib, 22E, 26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E,26R, 34R, 38K, 39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G,39G, 40G, 41S, 42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S,42K); and vi) (8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K).101. The derivative of any of embodiments 1-100, in the form of a sodiumor potassium salt thereof.102. The derivative of any of embodiments 1-101 which is a GLP-1receptor agonist.103. The derivative of embodiment 102, which is a full GLP-1 receptoragonist.104. The derivative of any of embodiments 1-103, which is biologicallyactive in vitro.105. The derivative of any of embodiments 1-104, which is potent invitro.106. The derivative of any of embodiments 1-105, which is capable ofactivating the human GLP-1 receptor.107. The derivative of any of embodiments 1-106 which is capable ofactivating the human GLP-1 receptor in an assay with whole cellsexpressing the human GLP-1 receptor, wherein the assay is performed inthe absence of HSA (0% HSA), and/or in the presence of HSA (1% HSA).108. The derivative of embodiment 107, where the response of the humanGLP-1 receptor is measured in a reporter gene assay, such as the assayof Example 9.109. The derivative of any of embodiments 104-108, wherein thebiological activity, or potency, in vitro is determined essentially asdescribed in Example 9.110. The derivative of any of embodiments 1-109, which has an in vitropotency corresponding to an EC₅₀ of 400 pM or below.111. The derivative of any of embodiments 1-110, which has an in vitropotency corresponding to an EC₅₀ of 300 pM or below.112. The derivative of any of embodiments 1-111, which has an in vitropotency corresponding to an EC₅₀ of 100 pM or below.113. The derivative of any of embodiments 1-112, which has an in vitropotency corresponding to an EC₅₀ of 75 pM or below.114. The derivative of any of embodiments 1-113, which has an in vitropotency corresponding to an EC₅₀ of 55 pM or below.115. The derivative of any of embodiments 1-114, which has an in vitropotency corresponding to an EC₅₀ of 40 pM or below.116. The derivative of any of embodiments 110-115, wherein the EC₅₀ isdetermined essentially as described in Example 9.117. The derivative of any of embodiments 1-116, which has an in vitropotency corresponding to an EC₅₀ of less than 40 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.118. The derivative of any of embodiments 1-117, which has an in vitropotency corresponding to an EC₅₀ of less than 30 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.119. The derivative of any of embodiments 1-118, which has an in vitropotency corresponding to an EC₅₀ of less than 20 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.120. The derivative of any of embodiments 1-119, which has an in vitropotency corresponding to an EC₅₀ of less than 8 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.121. The derivative of any of embodiments 1-120, which has an in vitropotency corresponding to an EC₅₀ of less than 5 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.122. The derivative of any of embodiments 1-121, which has an in vitropotency corresponding to an EC₅₀ of less than 3.5 times the EC₅₀ ofsemaglutide, wherein the EC₅₀ of semaglutide is determined in the sameway as the EC₅₀ of the derivative.123. The derivative of any of embodiments 117-122, wherein the EC₅₀ isdetermined essentially as described in Example 9.124. The derivative of any of embodiments 1-123, which is capable ofbinding to the GLP-1 receptor.125. The derivative of any of embodiments 1-124, which is capable ofbinding to the GLP-1 receptor at a low concentration of HSA (max. 0.001%final assay concentration).126. The derivative of any of embodiments 1-125, which is capable ofbinding to the GLP-1 receptor at a high concentration of HSA (2.0% finalassay concentration).127. The derivative of any of embodiments 124-126, wherein the bindingto the human GLP-1 receptor is measured in a competitive binding assay,such as the assay of Example 10.128. The derivative of any of embodiments 124-127, wherein the bindingto the human GLP-1 receptor in vitro is determined essentially asdescribed in Example 10.129. The derivative of any of embodiments 1-128, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 3.0 nM or below.130. The derivative of any of embodiments 1-129, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 2.0 nM or below.131. The derivative of any of embodiments 1-130, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 1.0 nM or below.132. The derivative of any of embodiments 1-131, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of 0.8 nM or below.133. The derivative of any of embodiments 129-132, wherein the IC₅₀ isdetermined essentially as described in Example 10, in a reaction withmax. 0.001% HSA (final assay concentration).134. The derivative of any of embodiments 1-133, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 3 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.135. The derivative of any of embodiments 1-134, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 2 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.136. The derivative of any of embodiments 1-135, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 1.5 times the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.137. The derivative of any of embodiments 1-136, which at a very lowconcentration of HSA is capable of binding to the human GLP-1 receptorwith an IC₅₀ of less than 1 time the IC₅₀ of semaglutide, wherein theIC₅₀ of semaglutide is determined in the same way as the IC₅₀ of thederivative.138. The derivative of any of embodiments 134-137, wherein the IC₅₀ isdetermined essentially as described in Example 10, in a reaction withmax. 0.001% HSA (final assay concentration).139. The derivative of any of embodiments 1-138, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 400 nM or below.140. The derivative of any of embodiments 1-139, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 300 nM or below.141. The derivative of any of embodiments 1-140, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 200 nM or below.142. The derivative of any of embodiments 1-141, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of 150 nM or below.143. The derivative of any of embodiments 139-142, wherein the IC₅₀ isdetermined essentially as described in Example 10, in a reaction with2.0% HSA (final assay concentration).144. The derivative of any of embodiments 1-143, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 1.5 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.145. The derivative of any of embodiments 1-144, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 1 time the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.146. The derivative of any of embodiments 1-145, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 0.8 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.147. The derivative of any of embodiments 1-146, which at 2.0% HSA(final assay concentration) is capable of binding to the human GLP-1receptor with an IC₅₀ of less than 0.35 times the IC₅₀ of semaglutide,wherein the IC₅₀ of semaglutide is determined in the same way as theIC₅₀ of the derivative.148. The derivative of any of embodiments 144-147, wherein the IC₅₀ isdetermined essentially as described in Example 10, in a reaction with2.0% HSA (final assay concentration).149. The derivative of any of embodiments 1-148, which has improvedpharmacokinetic properties.150. The derivative of any of embodiments 1-149, which has an increasedhalf-life and/or a decreased clearance.151. The derivative of any of embodiments 1-150, which is suitable foronce-monthly administration.152. The derivative of embodiment 151, for s.c. administration.153. The derivative of any of embodiments 149-152, wherein thederivative is tested in vivo in pharmacokinetic (PK) studies.154. The derivative of embodiment 153, wherein the derivative is testedin any suitable animal model, such as mouse, rat, monkey, dog, or pig.155. The derivative of any of embodiments 149-154, which is comparedwith semaglutide.156. The derivative of any of embodiments 1-155, which has an improvedterminal half-life (T½) in vivo in minipigs after i.v. administration ascompared to semaglutide.157. The derivative of any of embodiments 149-156, wherein the terminalhalf-life is determined in vivo in minipigs after i.v. administrationusing any suitable study protocol, such as the one described in Example11.158. The derivative of any of embodiments 149-157, wherein the terminalhalf-life is determined in vivo in minipigs after i.v. administration,essentially as described in Example 11.159. The derivative of any of embodiments 1-158, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least90 hours.160. The derivative of any of embodiments 1-159, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least100 hours.161. The derivative of any of embodiments 1-160, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least125 hours.162. The derivative of any of embodiments 1-161, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least140 hours.163. The derivative of any of embodiments 1-162, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least1.5 times the terminal half-life of semaglutide, determined in the sameway.164. The derivative of any of embodiments 1-163, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2 times the terminal half-life of semaglutide, determined in the sameway.165. The derivative of any of embodiments 1-164, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2.3 times the terminal half-life of semaglutide, determined in the sameway.166. The derivative of any of embodiments 1-165, which has a terminalhalf-life (T½) in vivo in minipigs after i.v. administration of at least2.6 times the terminal half-life of semaglutide, determined in the sameway.167. The derivative of any of embodiments 1-166, which is potent invivo.168. The derivative of any of embodiments 1-167, which is potent in vivowhen determined in any suitable animal model, such as mouse or pig.169. The derivative of embodiment 168, wherein the animal model is db/dbmouse.170. The derivative of any of embodiments 167-169, wherein the bloodglucose lowering effect is determined.171. The derivative of any of embodiments 167-170, wherein the bodyweight lowering effect is determined.172. The derivative of any of embodiments 1-171, wherein blood glucoselowering effect and/or body weight lowering effect is determined in vivoin db/db mouse using any suitable study protocol and methodology, e.g.as described in Example 12.173. The derivative of any of embodiments 1-172, wherein the bloodglucose lowering effect and/or the body weight lowering effect isdetermined in vivo in db/db mouse, essentially as described in Example12.174. The derivative of any of embodiments 1-173, which has the effect invivo of decreasing blood glucose after 48 hours, determined in asingle-dose study in a db/db mouse model.175. The derivative of embodiment 174, wherein the blood glucose isdecreased by at least 15%, as compared to the blood glucose level beforeadministration of the derivative.176. The derivative of any of embodiments 174-175, wherein the bloodglucose is decreased by at least 25%, as compared to the blood glucoselevel before administration of the derivative.177. The derivative of any of embodiments 174-176 wherein the bloodglucose is decreased by at least 35%, as compared to the blood glucoselevel before administration of the derivative.178. The derivative of any of embodiments 174-177, wherein the bloodglucose is decreased by at least 50%, as compared to the blood glucoselevel before administration of the derivative.179. The derivative of any of embodiments 1-178, which has the effect invivo of decreasing blood glucose after 72 hours, determined in asingle-dose study in a db/db mouse model.180. The derivative of any of embodiments 1-179, which has the effect invivo of decreasing blood glucose after 96 hours, determined in asingle-dose study in a db/db mouse model.181. The derivative of embodiment 180, wherein the blood glucose isdecreased by at least 5%, as compared to the blood glucose level beforeadministration of the derivative.182. The derivative of any of embodiments 180-181, wherein the bloodglucose is decreased by at least 10%, as compared to the blood glucoselevel before administration of the derivative.183. The derivative of any of embodiments 180-182, wherein the bloodglucose is decreased by at least 15%, as compared to the blood glucoselevel before administration of the derivative.184. The derivative of any of embodiments 180-183, wherein the bloodglucose is decreased by at least 20%, as compared to the blood glucoselevel before administration of the derivative.185. The derivative of any of embodiments 180-184, wherein the bloodglucose is decreased by at least 25%, as compared to the blood glucoselevel before administration of the derivative.186. The derivative of any of embodiments 1-185, which has the effect invivo of decreasing body weight after 48 hours, determined in asingle-dose study in a db/db mouse model.187. The derivative of embodiment 186, wherein the body weight isdecreased by at least 3%, as compared to the body weight beforeadministration of the derivative.188. The derivative of any of embodiments 186-187, wherein the bodyweight is decreased by at least 4%, as compared to the body weightbefore administration of the derivative.189. The derivative of any of embodiments 186-188, wherein the bodyweight is decreased by at least 5%, as compared to the body weightbefore administration of the derivative.190. The derivative of any of embodiments 186-184, wherein the bodyweight is decreased by at least 6%, as compared to the body weightbefore administration of the derivative.191. The derivative of any of embodiments 1-190, which has the effect invivo of decreasing body weight after 72 hours, determined in asingle-dose study in a db/db mouse model.192. The derivative of any of embodiments 1-191 which has the effect invivo of decreasing body weight after 96 hours, determined in asingle-dose study in a db/db mouse model.193. The derivative of embodiment 192, wherein the body weight isdecreased by at least 2%, as compared to the body weight beforeadministration of the derivative.194. The derivative of any of embodiments 192-193, wherein the bodyweight is decreased by at least 3%, as compared to the body weightbefore administration of the derivative.195. The derivative of any of embodiments 192-194, wherein the bodyweight is decreased by at least 4%, as compared to the body weightbefore administration of the derivative.196. The derivative of embodiment 168, wherein the animal model is pig.197. The derivative of embodiment 196, wherein the animal model is LYDpig.198. The derivative of any of embodiments 196-197, wherein the reductionin food intake is determined in an in vivo pharmacodynamic (PD) study.199. The derivative of any of embodiments 196-198, wherein the reductionin food intake is determined in vivo in pig using any suitable studyprotocol and methodology, e.g. as described in Example 13.200. The derivative of any of embodiments 196-199, wherein the reductionin food intake is determined in vivo in pig using any suitable studyprotocol and methodology, essentially as described in Example 13.201. The derivative of any of embodiments 1-200, which has the effect invivo of reducing food intake during a first period of 24 hours (0-24hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.202. The derivative of any of embodiments 1-201, which has the effect invivo of reducing food intake during a second period of 24 hours (24-48hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.203. The derivative of any of embodiments 1-202, which has the effect invivo of reducing food intake during a third period of 24 hours (48-72hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.204. The derivative of any of embodiments 1-203, which has the effect invivo of reducing food intake during a fourth period of 24 hours (72-96hours) after administration of a single dose of the derivative, whereinfood intake is determined in a single-dose study in a LYD pig model.205. A GLP-1 derivative selected from the following: Chem. 21, Chem. 22,Chem. 23, Chem. 24, Chem. 25, Chem. 26, Chem. 27, and Chem. 28; or apharmaceutically acceptable salt, amide, or ester thereof.206. A GLP-1 derivative selected from the chemical structures shown inany of Examples 1-8; or a pharmaceutically acceptable salt, amide, orester thereof.207. A GLP-1 derivative selected from the GLP-1 derivative names shownin any of Examples 1-8; or a pharmaceutically acceptable salt, amide, orester thereof.208. The derivative of any of embodiments 205-207, which is a derivativeaccording to any of embodiments 1-204.209. An intermediate product in the form of a GLP-1 analogue, whichcomprises the following amino acid changes when compared to GLP-1 (7-37)(SEQ ID NO: 1): i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K);ii) (8Aib, 22E, 26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib,22E, 26R, 34R, 38K, 39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R,38G, 39G, 40G, 41S, 42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G,41S, 42K); or vi) (8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K).210. An intermediate product in the form of a GLP-1 analogue, selectedfrom the following analogues of GLP-1 (7-37) (SEQ ID NO: 1):i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii) (8Aib, 22E,26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E, 26R, 34R, 38K,39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S,42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K); and vi)(8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K).211. A pharmaceutical composition comprising a derivative according toany of embodiments 1-208, or an analogue according to any of embodiments209-210, and a pharmaceutically acceptable excipient.212. A derivative according to any of embodiments 1-208, or an analogueaccording to any of embodiments 209-210, for use as a medicament.213. A derivative according to any of embodiments 1-208, or an analogueaccording to any of embodiments 209-210, for use in

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse.

214. Use of a derivative according to any of embodiments 1-208, or ananalogue according to any of embodiments 209-210, in the manufacture ofa medicament for

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo; (viii) prevention and/or treatment of cardiovascular diseases,such as syndrome X, atherosclerosis, myocardial infarction, coronaryheart disease, reperfusion injury, stroke, cerebral ischemia, an earlycardiac or early cardiovascular disease, left ventricular hypertrophy,coronary artery disease, hypertension, essential hypertension, acutehypertensive emergency, cardiomyopathy, heart insufficiency, exerciseintolerance, acute and/or chronic heart failure, arrhythmia, cardiacdysrhythmia, syncope, angina pectoris, cardiac bypass and/or stentreocclusion, intermittent claudication (atherosclerosis oblitterens),diastolic dysfunction, and/or systolic dysfunction; and/or reduction ofblood pressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse.

215. A method for

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis;

(v) prevention and/or treatment of eating disorders, such as obesity,e.g. by decreasing food intake, reducing body weight, suppressingappetite, inducing satiety; treating or preventing binge eatingdisorder, bulimia nervosa, and/or obesity induced by administration ofan antipsychotic or a steroid; reduction of gastric motility; delayinggastric emptying; increasing physical mobility; and/or prevention and/ortreatment of comorbidities to obesity, such as osteoarthritis and/orurine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

(xiii) prevention and/or treatment of sleep apnea; and/or

(xiv) prevention and/or treatment of abuse, such as alcohol abuse and/ordrug abuse;

wherein a pharmaceutically active amount of a derivative according toany of embodiments 1-208, or an analogue according to any of embodiments209-210, is administered.The following is a further set of particular embodiments of theinvention:1. A derivative of a GLP-1 like peptide of formula I:

Formula I: Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,wherein

Xaa₇ is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid,D-histidine, desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine;

Xaa₈ is Ala, Gly, Ser, Aib, (1-aminocyclopropyl) carboxylic acid, or(1-aminocyclobutyl) carboxylic acid;

Xaa₁₂ is Phe or Leu;

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Arg, Lys, Val, or Leu;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys, or Arg;

Xaa₂₅ is Ala or Val;

Xaa₂₆ is Arg or Lys;

Xaa₂₇ is Glu, Lys, or Leu;

Xaa₃₀ is Ala, Glu, or Arg;

Xaa₃₁ is Trp, Lys, or His;

Xaa₃₃ is Val, Lys, or Arg;

Xaa₃₄ is Lys, Arg, His, Asn, or Gln;

Xaa₃₅ is Gly or Ala;

Xaa₃₆ is Arg, Lys, or Gly;

Xaa₃₇ is Gly or Pro;

Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys;

Xaa₃₉ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro;

Xaa₄₁ is Ser, Gly, Ala, Glu, or Pro; and

Xaa₄₂ is Lys;

with the proviso that at least one of Xaa₁₈, Xaa₂₃, Xaa₂₇, Xaa₃₁, Xaa₃₆,or Xaa₃₈ is Lys;

wherein

Lys at Xaa₄₂ is a first K residue, and a Lys at one of Xaa₁₈, Xaa₂₃,Xaa₂₇, Xaa₃₁, Xaa₃₆, or Xaa₃₈ is a second K residue;

which derivative comprises a first and a second protracting moietyconnected to said first and second K residue, respectively, wherein thefirst and second protracting moiety is of formula Chem. 1:

HOOC—(CH₂)₁₈—CO—*;  Chem. 1:

or a pharmaceutically acceptable salt, amide, or ester thereof.2. The derivative of embodiment 1, wherein each of the first and thesecond protracting moiety is attached to the first and the second Kresidue, respectively, optionally via a first and a second linker,respectively.3. The derivative of embodiment 2, wherein the first and the secondlinker each incorporates an *—NH group, and a *—CO group.4. The derivative of any of embodiments 2-3, wherein each of the firstand the second linker comprises an element_1 of formula Chem. 2:

5. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₁₈ isthe second K residue.6. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₂₃ isthe second K residue.7. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₂₇ isthe second K residue.8. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₃₁ isthe second K residue.9. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₃₆ isthe second K residue.10. The derivative of any of embodiments 1-4, wherein a Lys at Xaa₃₈ isthe second K residue.11. A GLP-1 derivative selected from the following: Chem. 21, Chem. 22,Chem. 23, Chem. 24, Chem. 25, Chem. 26, Chem. 27, and Chem. 28; or apharmaceutically acceptable salt, amide, or ester thereof.12. An intermediate product in the form of a GLP-1 analogue, whichcomprises the following amino acid changes when compared to GLP-1 (7-37)(SEQ ID NO: 1):i) (8Aib, 22E, 26R, 27K, 34R, 38G, 39G, 40G, 41S, 42K); ii) (8Aib, 22E,26R, 31K, 34R, 38G, 39G, 40G, 41S, 42K); iii) (8Aib, 22E, 26R, 34R, 38K,39G, 40G, 41S, 42K); iv (8Aib, 22E, 23K, 26R, 34R, 38G, 39G, 40G, 41S,42K); v) (8Aib, 22E, 26R, 34R, 36K, 38G, 39G, 40G, 41S, 42K); or vi)(8Aib, 18K, 22E, 26R, 34R, 38G, 39G, 40G, 41S, 42K).13. A pharmaceutical composition comprising a derivative according toany of embodiments 1-11, or an analogue according to embodiment 12, anda pharmaceutically acceptable excipient.14. A derivative according to any of embodiments 1-11, or an analogueaccording to embodiment 12, for use as a medicament.15. A derivative according to any of embodiments 1-11, or an analogueaccording to embodiment 12, for use in

(i) prevention and/or treatment of all forms of diabetes, such ashyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetesof the young), gestational diabetes, and/or for reduction of HbA1C;

(ii) delaying or preventing diabetic disease progression, such asprogression in type 2 diabetes, delaying the progression of impairedglucose tolerance (IGT) to insulin requiring type 2 diabetes, delayingor preventing insulin resistance, and/or delaying the progression ofnon-insulin requiring type 2 diabetes to insulin requiring type 2diabetes;

(iii) improving β-cell function, such as decreasing β-cell apoptosis,increasing β-cell function and/or β-cell mass, and/or for restoringglucose sensitivity to β-cells;

(iv) prevention and/or treatment of cognitive disorders and/orneurodegenerative disorders, such as Alzheimer's disease, Parkinson'sdisease, and/or multiple sclerosis; (v) prevention and/or treatment ofeating disorders, such as obesity, e.g. by decreasing food intake,reducing body weight, suppressing appetite, inducing satiety; treatingor preventing binge eating disorder, bulimia nervosa, and/or obesityinduced by administration of an antipsychotic or a steroid; reduction ofgastric motility; delaying gastric emptying; increasing physicalmobility; and/or prevention and/or treatment of comorbidities toobesity, such as osteoarthritis and/or urine incontinence;

(vi) prevention and/or treatment of diabetic complications, such asangiopathy; neuropathy, including peripheral neuropathy; nephropathy;and/or retinopathy;

(vii) improving lipid parameters, such as prevention and/or treatment ofdyslipidemia, lowering total serum lipids; increasing HDL; loweringsmall, dense LDL; lowering VLDL; lowering triglycerides; loweringcholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human;inhibiting generation of apolipoprotein a (apo(a)) in vitro and/or invivo;

(viii) prevention and/or treatment of cardiovascular diseases, such assyndrome X, atherosclerosis, myocardial infarction, coronary heartdisease, reperfusion injury, stroke, cerebral ischemia, an early cardiacor early cardiovascular disease, left ventricular hypertrophy, coronaryartery disease, hypertension, essential hypertension, acute hypertensiveemergency, cardiomyopathy, heart insufficiency, exercise intolerance,acute and/or chronic heart failure, arrhythmia, cardiac dysrhythmia,syncope, angina pectoris, cardiac bypass and/or stent reocclusion,intermittent claudication (atherosclerosis oblitterens), diastolicdysfunction, and/or systolic dysfunction; and/or reduction of bloodpressure, such as reduction of systolic blood pressure;

(ix) prevention and/or treatment of gastrointestinal diseases, such asinflammatory bowel disease, short bowel syndrome, or Crohn's disease orcolitis; dyspepsia, and/or gastric ulcers; and/or inflammation, such aspsoriasis, psoriatic arthritis, rheumatoid arthritis, and/or systemiclupus erythematosus;

(x) prevention and/or treatment of critical illness, such as treatmentof a critically ill patient, a critical illness poly-nephropathy (CIPNP)patient, and/or a potential CIPNP patient; prevention of development ofcritical illness or CIPNP; prevention, treatment and/or cure of systemicinflammatory response syndrome (SIRS) in a patient; prevention orreduction of the likelihood of a patient suffering from bacteremia,septicemia, and/or septic shock during hospitalization; and/orstabilising blood glucose, insulin balance and optionally metabolism inintensive care unit patients with acute illness;

(xi) prevention and/or treatment of polycystic ovary syndrome (PCOS);

(xii) prevention and/or treatment of cerebral disease, such as cerebralischemia, cerebral haemorrhage, and/or traumatic brain injury;

-   -   (xiii) prevention and/or treatment of sleep apnea; and/or    -   (xiv) prevention and/or treatment of abuse, such as alcohol        abuse and/or drug abuse.

EXAMPLES

This experimental part starts with a list of abbreviations, and isfollowed by a section including general methods for synthesising andcharacterising analogues and derivatives of the invention. Then followsa number of examples which relate to the preparation of specific GLP-1derivatives, and at the end a number of examples have been includedrelating to the activity and properties of these analogues andderivatives (section headed pharmacological methods). The examples serveto illustrate the invention.

Materials and Methods LIST OF ABBREVIATIONS

-   Aib: α-aminoisobutyric acid (2-Aminoisobutyric acid)-   AcOH: acetic acid-   API: Active Pharmaceutical Ingredient-   AUC: Area Under the Curve-   BG: Blood Glucose-   BHK Baby Hamster Kidney-   BW: Body Weight-   Boc: t-butyloxycarbonyl-   Bom: benzyloxymethyl-   BSA: Bovine serum albumin-   Bzl: benzyl-   CAS: Chemical Abstracts Service-   Clt: 2-chlorotrityl-   collidine: 2,4,6-trimethylpyridine-   DCM: dichloromethane-   Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl-   DesH: des-amino histidine (imidazopropionic acid or    3-(Imidazol-5-yl)propanoic acid), Imp)-   DIC: diisopropylcarbodiimide-   DIPEA: diisopropylethylamine-   DMAP: 4-dimethylaminopyridine-   DMEM: Dulbecco's Modified Eagle's Medium (DMEM)-   DooaSuc: 8-amino-3,6-dioxaoctyl succinamic acid-   EDTA: ethylenediaminetetraacetic acid-   EGTA: ethylene glycol tetraacetic acid-   FCS: Fetal Calf Serum-   Fmoc: 9-fluorenylmethyloxycarbonyl-   HATU: (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa    fluorophosphate)-   HBTU: (2-(1H-benzotriazol-1-yl-)-1,1,3,3 tetramethyluronium    hexafluorophosphate)-   HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-   HFIP 1,1,1,3,3,3-hexafluoro-2-propanol or hexafluoroisopropanol-   HOAt: 1-hydroxy-7-azabenzotriazole-   HOBt: 1-hydroxybenzotriazole-   HPLC: High Performance Liquid Chromatography-   HSA: Human Serum Albumin-   IBMX: 3-isobutyl-1-methylxanthine-   Imp: Imidazopropionic acid or 3-(Imidazol-5-yl)propanoic acid) (also    referred to as des-amino histidine, DesH)-   Inp: isonipecotic acid-   i.v. intravenously-   ivDde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl-   IVGTT: Intravenous Glucose Tolerance Test-   LCMS: Liquid Chromatography Mass Spectroscopy-   LYD: Landrace Yorkshire Duroc-   MALDI-MS: See MALDI-TOF MS-   MALDI-TOF MS: Matrix-Assisted Laser Desorption/Ionisation Time of    Flight Mass Spectroscopy-   MeOH: methanol-   Mmt: 4-methoxytrityl-   Mtt: 4-methyltrityl-   NMP: N-methyl pyrrolidone-   OBz: benzoyl ester-   OEG: 8-amino-3,6-dioxaoctanoic acid-   OPfp: pentafluorophenoxy-   OPnp: para-nitrophenoxy-   OSu: O-succinimidyl esters (hydroxysuccinimide esters)-   OtBu: tert butyl ester-   Oxyma Pure®: Cyano-hydroxyimino-acetic acid ethyl ester-   Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-   PBS: Phosphate Buffered Saline-   PD: Pharmacodynamic-   Pen/Strep: Penicillin/Streptomycin-   PK: Pharmacokinetic-   RP: Reverse Phase-   RP-HPLC: Reverse Phase High Performance Liquid Chromatography-   RT: Room Temperature-   Rt: Retention time-   s.c.: Subcutaneously-   SD: Standard Deviation-   SEC-HPLC: Size Exclusion High Performance Liquic Chromatography-   SEM: Standard Error of Mean-   SPA: Scintillation Proximity Assay-   SPPS: Solid Phase Peptide Synthesis-   TBME: tert-butyl methyl ether-   tBu: tert. butyl-   TFA: trifluoroacetic acid-   TIS: triisopropylsilane-   TLC: Thin Layer Chromatography-   Tos: tosylate (or pare-toluenesulfonyl)-   TotaGlyc: 13-amino-4,7,10-trioxatridecayl diglycolamic acid-   Tris: tris(hydroxymethyl)aminomethane or    2-amino-2-hydroxymethyl-propane-1,3-diol-   Trt: triphenylmethyl (trityl)-   Trx: tranexamic acid-   TtdSuc: 13-amino-4,7,10-trioxatridecayl succinamic acid-   UPLC: Ultra Performance Liquid Chromatography

Special Materials

-   Eicosanedioic acid mono-tert-butyl ester-   Docosanedioic acid mono-tert-butyl ester-   Nonadecanedioic acid mono-tert-butyl ester Nonadecanedioic acid-   Fmoc-8-amino-3,6-dioxaoctanoic acid-   Fmoc-8-amino-3,6-dioxaoctyl succinamic acid-   Fmoc-13-amino-4,7,10-trioxatridecayl succinamic acid-   Fmoc-13-amino-4,7,10-trioxatridecayl diglycolamic acid-   Fmoc-tranexamic acid-   Fmoc-Lys(Mtt)-OH-   Fmoc-Glu-OtBu-   Boc-Lys(Fmoc)-OH-   4-Dimethylaminopyridine (DMAP)-   tert-Butyl methyl ether (TBME)

The preparation of eicosanedioic acid mono-tert-butyl ester,docosanedioic acid mono-tert-butyl ester, and nonadecanedioic acidmono-tert-butyl ester is described in section 2 below, and the elevenlast-mentioned materials are commercially available.

Chemical Methods

This section is divided in two: Section A relating to general methods(of preparation (A1); and of detection and characterisation (A2)), andsection B, in which the preparation and characterisation of a number ofspecific example compounds is described.

A. General Methods A1. Methods of Preparation

This section relates to methods for solid phase peptide synthesis (SPPSmethods, including methods for de-protection of amino acids, methods forcleaving the peptide from the resin, and for its purification), as wellas methods for detecting and characterising the resulting peptide (LCMS,MALDI, and UPLC methods). The solid phase synthesis of peptides may insome cases be improved by the use of di-peptides protected on thedi-peptide amide bond with a group that can be cleaved under acidicconditions such as, but not limited to, 2-Fmoc-oxy-4-methoxybenzyl, or2,4,6-trimethoxybenzyl. In cases where a serine or a threonine ispresent in the peptide, pseudoproline di-peptides may be used (availablefrom, e.g., Novabiochem, see also W. R. Sampson (1999), J. Pep. Sci. 5,403). The Fmoc-protected amino acid derivatives used were the standardrecommended: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH,Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH,Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH,Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH,Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH,or, Fmoc-Val-OH etc. supplied from e.g. Anaspec, Bachem, Iris Biotech,or Novabiochem. Where nothing else is specified the natural L-form ofthe amino acids are used. The N-terminal amino acid was Boc protected atthe alpha amino group (e.g. Boc-His(Boc)-OH, or Boc-His(Trt)-OH forpeptides with His at the N-terminus). In case of modular albumin bindingmoiety attachment using SPPS the following suitably protected buildingblocks such as but not limited to Fmoc-8-amino-3,6-dioxaoctanoic acid,Fmoc-tranexamic acid, Fmoc-isonipecotic acid, Fmoc-Glu-OtBu,Fmoc-Lys(Fmoc)-OH were used supplied from e.g. Anaspec, Bachem, IrisBiotech, or Novabiochem. Eicosanedioic acid mono-tert-butyl ester,docosanedioic acid mono-tert-butyl ester, and nonadecanedioic acidmono-tert-butyl ester can be prepared as described below. All operationsstated below were performed at 250-μmol synthesis scale.

1. Synthesis of Resin Bound Protected Peptide Backbone Method: SPPS_P

SPPS_P was performed on a Prelude Solid Phase Peptide Synthesizer fromProtein Technologies (Tucson, Ariz. 85714 U.S.A.) at 250-μmol scaleusing six fold excess of Fmoc-amino acids (300 mM in NMP with 300 mMHOAt or Oxyma Pure®) relative to resin loading, e.g. low loadFmoc-Gly-Wang (0.35 mmol/g). Fmoc-deprotection was performed using 20%piperidine in NMP. Coupling was performed using 3:3:3:4 amino acid/(HOAtor Oxyma Pure®)/DIC/collidine in NMP. NMP and DCM top washes (7 ml, 0.5min, 2×2 each) were performed between deprotection and coupling steps.Coupling times were generally 60 minutes. Some amino acids including,but not limited to Fmoc-Arg(Pbf)-OH, Fmoc-Aib-OH or Boc-His(Trt)-OH were“double coupled”, meaning that after the first coupling (e.g. 60 min),the resin is drained and more reagents are added (amino acid, (HOAt orOxyma Pure®), DIC, and collidine), and the mixture allowed to reactagain (e.g. 60 min).

Method: SPPS_L

SPPS_L was performed on a microwave-based Liberty peptide synthesiserfrom CEM Corp. (Matthews, N.C. 28106, U.S.A.) at 250-μmol or 100-μmolscale using six fold excess of Fmoc-amino acids (300 mM in NMP with 300mM HOAt or Oxyma Pure®) relative to resin loading, e.g. low loadFmoc-Gly-Wang (0.35 mmol/g). Fmoc-deprotection was performed using 5%piperidine in NMP at up to 75° C. for 30 seconds where after the resinwas drained and washed with NMP and the Fmoc-deprotection was repeatedthis time for 2 minutes at 75° C. Coupling was performed using 1:1:1amino acid/(HOAt or Oxyma Pure®)/DIC in NMP. Coupling times andtemperatures were generally 5 minutes at up to 75° C. Longer couplingtimes were used for larger scale reactions, for example 10 min.Histidine amino acids were double coupled at 50° C., or quadruplecoupled if the previous amino acid was sterically hindered (e.g. Aib).Arginine amino acids were coupled at RT for 25 minutes and then heatedto 75° C. for 5 min. Some amino acids such as but not limited to Aib,were “double coupled”, meaning that after the first coupling (e.g. 5 minat 75° C.), the resin is drained and more reagents are added (aminoacid, (HOAt or Oxyma Pure®) and DIC), and the mixture is heated again(e.g. 5 min at 75° C.). NMP washes (5×10 ml) were performed betweendeprotection and coupling steps.

2. Synthesis of Albumin Binder

Eicosanedioic acid mono-tert-butyl ester can be prepared as is known inthe art, e.g. as described in WO 2010102886 A1.

Docosanedioic Acid Mono-Tert-Butyl Ester can be Prepared as Described inthe Following:

1 M solution of borane-tetrahydrofuran complex in tetrahydrofuran (94.1mL, 94.1 mmol) was added dropwise to a solution of icosanedioic acidmono-tert-butyl ester (25.0 g, 62.7 mmol) in dry tetrahydrofuran (140mL) at 0 C under argon. The resulting solution was stirred at 0 C for 2hrs, then the cooling bath was removed and the mixture stirred at roomtemperature overnight. Saturated aqueous solution of sodium bicarbonate(300 mL) and water (100 mL) were added and the resulting mixture wasextracted with dichloromethane (250 mL, 2×100 mL). Combined organicextracts were dried over anhydrous sodium sulfate and evaporated todryness. The residue was purified by column chromatography on silicagel(eluent: dichloromethane/methanol 99:1). Fractions with pure productwere evaporated, residue was chromatographed again (eluent:dichloromethane/methanol 99:1). Products were combined and dried invacuo yielding 20-hydroxy-icosanoic acid tert-butyl ester as whitesolid.

Yield: 16.50 g (68%).

¹H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 3.64 (t, J=6.6 Hz, 2H),2.20 (t, J=7.5 Hz, 2H); 1.65-1.51 (m, 4H); 1.45 (s, 9H); 1.36-1.21 (m,30H).

The above prepared alcohol (16.5 g, 42.9 mmol) was dissolved in drydichloromethane (90 mL). Triethylamine (9.00 mL, 64.4 mmol) was added,reaction mixture was cooled to 0 C and mesyl chloride (4.00 mL, 51.5mmol) was added dropwise. After 1 hr the reaction mixture was allowed towarm to room temperature and has been stirred overnight. Water (1.5 mL)was added and the mixture was stirred 30 minutes. Solvents wereevaporated, ethyl acetate was added (200 mL) and the mixture wasextracted with 1 M hydrochloric acid (2×100 mL), 5% solution of sodiumcarbonate (2×100 mL) and water (100 mL). After drying with anhydroussodium sulfate, filtration and evaporation of solvents20-methanesulfonyloxy-icosanoic acid tert-butyl ester was obtained aswhite solid.

Yield: 19.80 g (100%).

¹H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 4.22 (t, J=6.6 Hz, 2H);3.01 (s, 3H); 2.20 (t, J=7.5 Hz, 2H); 1.81-1.68 (m, 2H); 1.63-1.51 (m,2H); 1.44 (s, 9H); 1.34-1.22 (m, 30H).

The above prepared mesylate (17.8 g, 38.5 mmol) was dissolved in acetone(250 mL) and lithium bromide (6.69 g, 77.0 mmol) was added and thereaction mixture was refluxed overnight. After cooling down solvent wasevaporated, ethyl acetate (300 mL) was added and the mixture wasextracted with 5% solution of sodium bicarbonate (3×170 mL). Combinedorganic extracts were dried over anhydrous sodium sulfate andevaporated. Product was dried in vacuo to yield 20-bromo-icosanoic acidtert-butyl ester as white solid.

Yield: 17.10 g (99%).

¹H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 3.41 (t, J=6.9 Hz, 2H);2.20 (t, J=7.4 Hz, 2H); 1.90-1.77 (m, 2H); 1.64-1.50 (m, 2H); 1.43 (s,9H); 1.34-1.13 (m, 30H).

Sodium hydride (60% dispersion in mineral oil, 3.96 g, 99.0 mmol) wasdissolved in N,N-dimethylformamide (100 mL) under nitrogen. Dimethylmalonate (22.6 mL, 198 mmol) was added and the reaction mixture washeated briefly at 100 C, then cooled to room temperature and thesolution of above prepared 20-bromo-icosanoic acid tert-butyl ester(14.8 g, 33.0 mmol) in N,N-dimethylformamide (150 mL) was added. Thereaction mixture was heated at 100 C for 4 hrs. After cooling to roomtemperature, ethyl acetate (150 mL) was added and the organic solutionwas washed with saturated aqueous ammonium chloride (3×100 mL) and brine(100 mL), dried over anhydrous sodium sulfate and evaporated to dryness.Residue was purified by column chromatography on silicagel (eluent:hexane/ethyl acetate 96:4 to 93:7) giving2-methoxycarbonyl-docosanedioic acid 22-tert-butyl ester 1-methyl esteras white solid.

Yield: 16.10 g (97%).

¹H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 3.74 (s, 6H); 3.36 (t,J=7.5 Hz, 1H); 2.20 (t, J=7.5 Hz, 2H); 1.95-1.84 (m, 2H); 1.64-1.51 (m,2H); 1.44 (s, 9H); 1.34-1.21 (m, 32H).

The above prepared 2-methoxycarbonyl-docosanedioic acid 22-tert-butylester 1-methyl ester (16.1 g, 32.3 mmol) was dissolved intetrahydrofuran (85 mL) and solution of lithium hydroxide monohydrate(4.07 g, 96.9 mmol) in water (75 mL) was added. The reaction mixture wasstirred at room temperature overnight, then it was acidified with 1 Mhydrochloric acid and extracted with ethyl acetate (4×150 mL). Organicextracts were combined, dried over anhydrous sodium sulfate andevaporated. Product was dried in vacuo to yield 2-carboxy-docosanedioicacid 22-tert-butyl ester as white solid.

Yield: 14.50 g (95%).

¹H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 3.44 (t, J=7.4 Hz, 1H);2.22 (t, J=7.5 Hz, 2H); 2.00-1.89 (m, 2H); 1.63-1.52 (m, 2H); 1.45 (s,9H); 1.37-1.20 (m, 32H).

2-Carboxy-docosanedioic acid 22-tert-butyl ester (14.5 g, 30.8 mmol) wasdissolved in toluene (170 mL) and refluxed at 110 C for 48 hrs. Solventwas evaporated, residue was purified by column chromatography onsilicagel (eluent: dichloromethane/methanol 97:3) giving the titledcompound as white solid.

Yield: 5.25 g (40%).

Total yield: 5.25 g (25%)

1H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 2.35 (t, J=7.5 Hz, 2H);2.21 (t, J=7.5 Hz, 2H); 1.68-1.53 (m, 4H); 1.45 (s, 9H); 1.35-1.22 (m,32H).

Nonadecanedioic Acid Mono-Tert-Butyl Ester can be Prepared as Describedin the Following:

A suspension of nonadecanedioic acid (26.1 g, 79.5 mmol) in mixture oftoluene (140 mL) and t-butanol (32 mL, 334.8 mmol, 4.4 eq.) was heatedto reflux temperature (97° C.). The mixture became a clear yellowsolution. DMAP (1.9 g, 15.2 mmol, 0.2 eq.) was added, followed by thedropwise addition of Boc₂O in toluene (75 mL) over 90 minutes. HeavyCO₂-evolution was observed. The mixture was stirred at refluxtemperature overnight and concentrated to a white slurry. Cold toluene(200 mL) was added and the solids were removed via filtration, washedwith toluene and dried in vacuo (45° C.) (6.2 g, starting material). Thefiltrate was concentrated (45° C.) and heptane (350 mL) was added to theoily residue. The white suspension was stirred for 1 hour at 0° C. andthe solids were isolated via filtration. The buttery-like filter residuewas dissolved in TBME and rinsed through the filter. The heptanefiltrate and TBME filtrate were concentrated separately. Heptane residue(10 g) contained mostly di-ester (ca. 80%) and the TBME residue (13.3 g)contained mostly mono-ester (ca. 80%). The TBME residue was purified byflash chromatography (Silica: 500 g, eluent: CH₂Cl₂/IPA 98:2 to 97:3).The title compound was obtained as a white solid (10.3 g, 33%).

1H NMR spectrum (300 MHz, CDCl₃, delta_(H)): 2.35 (t, J=7.6 Hz, 2H);2.20 (t, J=7.6 Hz, 2H); 1.68-1.53 (m, 4H); 1.43 (s, 9H); 1.39-1.22 (m,26H).

3. Attachment of Side Chains to Resin Bound Protected Peptide Backbone

When an acylation is present on a lysine side chain, the epsilon aminogroup of lysine to be acylated was protected with either Mtt, Mmt, Dde,ivDde, or Boc, depending on the route for attachment of the protractingmoiety and linker. Dde- or ivDde-deprotection was performed with 2%hydrazine in NMP (2×20 ml, each 10 min) followed by NMP washings (4×20ml). Mtt- or Mmt-deprotection was performed with 2% TFA and 2-3% TIS inDCM (5×20 ml, each 10 min) followed by DCM (2×20 ml), 10% MeOH and 5%DIPEA in DCM (2×20 ml) and NMP (4×20 ml) washings, or by treatment withhexafluoroisopropanol/DCM (75:25, 5×20 ml, each 10 min) followed bywashings as above. In some cases the Mtt group was removed by automatedsteps on the Liberty peptide synthesiser. Mtt deprotection was performedwith hexafluoroisopropanol or hexafluoroisopropanol/DCM (75:25) at roomtemperature for 30 min followed by washing with DCM (7 ml×5), followedby NMP washings (7 ml×5). The protracting moiety and/or linker can beattached to the peptide either by acylation of the resin bound peptideor by acylation in solution of the unprotected peptide. In case ofattachment of the protracting moiety and/or linker to the protectedpeptidyl resin the attachment can be modular using SPPS and suitablyprotected building blocks.

Method: SC_P

The N-ε-lysine protection group was removed as described above and thechemical modification of the lysine was performed by one or moreautomated steps on the Prelude peptide synthesiser using suitablyprotected building blocks as described above. Double couplings wereperformed as described in SPPS_P with 3 hours per coupling.

Method: SC_L

The N-ε-lysine protection group was removed as described above and thechemical modification of the lysine was performed by one or moreautomated steps on the Liberty peptide synthesiser using suitablyprotected building blocks as described above. Double couplings wereperformed as described in SPPS_L.

4. Cleavage of Resin Bound Peptide with or without Attached Side Chainsand Purification

Method: CP_M1

After synthesis the resin was washed with DCM, and the peptide wascleaved from the resin by a 2-3 hour treatment with TFA/TIS/water(95/2.5/2.5 or 92.5/5/2.5) followed by precipitation with diethylether.The peptide was dissolved in a suitable solvent (such as, e.g., 30%acetic acid) and purified by standard RP-HPLC on a C18, 5 μm column,using acetonitrile/water/TFA. The fractions were analysed by acombination of UPLC, MALDI and LCMS methods, and the appropriatefractions were pooled and lyophilised.

If desired the peptide counter ion can be exchanged to sodium usingmethods known in the art. As an example approx. 2 g peptide wasdissolved in 250 ml acetonitrile/water (50/50) and loaded onto a WatersX-Bridge C8, 5 μM, 50×250 mm column on a preparative RP-HPLC system.Following loading, the column was washed with water for 8 min at a flowrate of 60 ml/min and 0.01 N NaOH pH 11 at a flow rate of 60 ml/min for2×8 min. The sodium salt of the peptide was eluted using an isocraticflow of water at 60 ml/min for 10 min followed by a linear gradient of5% to 85% acetonitrile over 30 min.

Method: CP_M2

After synthesis the resin was washed with DCM, and the peptide wascleaved from the resin by a 2-3 hour treatment with TFA/TIS/water(95/2.5/2.5 or 92.5/5/2.5) followed by precipitation with diethylether.The peptide was dissolved in a suitable solvent (such as, e.g., 30%acetic acid) and purified by standard RP-HPLC on a Kinetex C18, 5 μmcolumn, eluting with a binary mixture of 0.09Mdiammoniumhydrogenphosphate in water/acetonitrile (90:10, pH 3.0) andacetonitrile/2-propanol/water (60:20:20). The peptide was then furtherpurified by standard RP-HPLC on a C18, 5 μm column, usingacetonitrile/water/TFA. The fractions were analysed by a combination ofUPLC, MALDI and LCMS methods, and the appropriate fractions were pooledand lyophilised.

If desired the peptide counter ion can be exchanged to sodium using themethods known in the art. As an example approx. 2 g peptide wasdissolved in 250 ml acetonitrile/water (50/50) and loaded onto a WatersX-Bridge C8, 5 μM, 50×250 mm column on a preparative RP-HPLC system.Following loading, the column was washed with water for 8 min at a flowrate of 60 ml/min and 0.01 N NaOH pH 11 at a flow rate of 60 ml/min for2×8 min. The sodium salt of the peptide was eluted using an isocraticflow of water at 60 ml/min for 10 min followed by a linear gradient of5% to 85% acetonitrile over 30 min.

A2. General Methods for Detection and Characterisation 1. LC-MS MethodsMethod: LCMS01

LCMS01v1 was performed on a setup consisting of Waters Acquity UPLCsystem and LCT Premier XE mass spectrometer from Micromass. Eluents: A:0.1% Formic acid in water; B: 0.1% Formic acid in acetonitrile. Theanalysis was performed at RT by injecting an appropriate volume of thesample (preferably 2-10 μl) onto the column which was eluted with agradient of A and B. The UPLC conditions, detector settings and massspectrometer settings were: Column: Waters Acquity UPLC BEH, C-18, 1.7μm, 2.1 mm×50 mm. Gradient: Linear 5%-95% acetonitrile during 4.0 min(alternatively 8.0 min) at 0.4 ml/min. Detection: 214 nm (analogueoutput from TUV (Tunable UV detector)) MS ionisation mode: API-ES. Scan:100-2000 amu (alternatively 500-2000 amu), step 0.1 amu.

2. UPLC Method Method: UPLC02

The RP-analysis was performed using a Waters UPLC system fitted with adual band detector. UV detections at 214 nm and 254 nm were collectedusing an ACQUITY UPLC BEH130, C18, 130 Å, 1.7 μm, 2.1 mm×150 mm column,40° C. The UPLC system was connected to two eluent reservoirscontaining: A: 99.95% H₂O, 0.05% TFA; B: 99.95% CH₃CN, 0.05% TFA. Thefollowing linear gradient was used: 95% A, 5% B to 95% A, 5% B over 16minutes at a flow-rate of 0.40 ml/min.

3. MALDI-MS Method Method: MALDI01v01

Molecular weights were determined using matrix-assisted laser desorptionand ionisation time-of-flight mass spectroscopy, recorded on a Microflexor Autoflex (Bruker). A matrix of alpha-cyano-4-hydroxy cinnamic acidwas used.

B. Preparation of Example Compounds Example 1N{Epsilon-27}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27,Arg34]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 2.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.6 min

MALDI01v01: calc. m/z=5649; found m/z=5648.

Example 2N{Epsilon-31}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys31,Arg34]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 3.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.6 min

MALDI01v01: calc. m/z=5593; found m/z=5590.

Example 3N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.8 min

MALDI01v01: calc. m/z=5722; found m/z=5720.

Example 4N{Epsilon-23}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Lys23,Arg26,Arg34]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 5.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.6 min

MALDI01v01: calc. m/z=5651; found m/z=5649.

Example 5N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 6.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.3 min

MALDI01v01: calc. m/z=5623; found m/z=5621.

Example 6N{Epsilon-18}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Lys18,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 7.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.8 min

LCMS01: Rt=2.6 min, m/3=1898; m/4=1424; m/3=1139

Example 7N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]hexanoyl]amino]hexanoyl]Lys-Gly-Gly-Ser-N{Epsilon}[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]hexanoyl]amino]hexanoyl]Lys

The peptide is SEQ ID NO: 4.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=9.8 min

LCMS01: Rt=2.3 min, m/3=1885; m/4=1415; m/5=1131; m/6=943

Example 8N{Epsilon-27}-[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-[Aib8,Glu22,Arg26,Lys27,Arg34]-GLP-1-(7-37)-peptidyl-Gly-Gly-Gly-Ser-N{Epsilon}[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]Lys

The peptide is SEQ ID NO: 2.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=8.9 min

MALDI01: calc. m/z=5303; found m/z=5302.

Example 9N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(21-carboxyhenicosanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(21-carboxyhenicosanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=12.3 min

LCMS01: Rt=2.7; m/3=1927; m/4=1444; m/5=1156

Example 10N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}3-[2-[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylLys-Gly-Gly-Ser-N{Epsilon}3-[2-[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylLys

Synthesis method: SPPS_P; SC_P; CP_M2

UPLC02: Rt=11.2 min

LCMS01: Rt=2.7; m/3=1880; m/4=1410; m/5=1128

Example 11N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Ser-Pro-Glu-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 14.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.7 min

LCMS01: Rt=2.7 min; m/3=1945; m/4=1460; m/5=1168

Example 12N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Pro-Glu-Gly-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 12.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.8 min

LCMS01: Rt=2.7 min; m/3=1935 m/4=1452; m/5=1162

Example 13N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Ser-Ala-Glu-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 13.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.7 min

LCMS01: Rt=2.7 min; m/3=1937; m/4=1453; m/5=1162

Example 14N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Ala-Glu-Ser-Pro-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 9.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=12 min

LCMS01: Rt=2.8 min; m/3=1917; m/4=1438; m/5=1151

Example 15N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Pro-Ala-Ser-Glu-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 11.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=12 min

LCMS01: Rt=2.8 min; m/3=1917; m/4=1438; m/5=1151

Example 16N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly-Pro-Ala-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 10.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=12 min

LCMS01: Rt=2.8 min; m/3=1907; m/4=1431; m/5=1145

Example 17N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.3 min

LCMS01: Rt=2.7 min; m/4=1577; m/5=1262

Example 18N{Alpha}([Imp7,Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 8.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.5 min

LCMS01: Rt=2.7 min; m/4=1572; m/5=1258

Example 19N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 4.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.7 min

LCMS01: Rt=2.6 min; m/4=1507; m/5=1206

Example 20N{Alpha}([Imp7,Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

The peptide is SEQ ID NO: 8.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.9 min

LCMS01: Rt=2.6 min; m/4=1503; m/5=1203

Example 21N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[4-[3-[2-[2-[3-[[(4S)-4-carboxy-4-[[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino]butanoyl]amino]propoxy]ethoxy]ethoxy]propylamino]-4-oxobutanoyl]Lys-Gly-Gly-Ser-N{Epsilon}[4-[3-[2-[2-[3-[[(4S)-4-carboxy-4-[[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino]butanoyl]amino]propoxy]ethoxy]ethoxy]propylamino]-4-oxobutanoyl]Lys

The peptide is SEQ ID NO: 4.

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.1 min

LCMS01: Rt=2.7 min; m/3=1897; m/4=1423; m/5=1139

Example 22N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[3-[2-[2-[3-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-oxoethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[3-[2-[2-[3-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-oxoethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.7 min

LCMS01: Rt=2.6 min; m/3=1834; m/4=1376; m/5=1101

Example 23N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[4-[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]ethylamino]-4-oxobutanoyl]Lys-Gly-Gly-Ser-N{Epsilon}[4-[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]ethylamino]-4-oxobutanoyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=11.1 min

LCMS01: Rt=2.7 min; m/4=1401.3; m/5=1121

Example 24N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.7 min

LCMS01: Rt=2.6 min; m/4=1721; m/5=1377

Example 25N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_L; SC_L; CP_M1

UPLC02: Rt=9.0 min

LCMS01: Rt=2.2 min, m/4=1570; m/5=1257

Example 26N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(18-carboxyoctadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[[4-[(18-carboxyoctadecanoylamino)methyl]cyclohexanecarbonyl]amino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_P; CP_M1

UPLC02: Rt=10.5 min

LCMS01: Rt=2.7 min; m/4=1425; m/5=1140

Example 27N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_L; CP_M2

UPLC02: Rt=8.8 min

LCMS01: Rt=2.2 min; m/4=1643; m/5=1315

Example 28N{Alpha}([Aib8,Glu22,Arg26,Arg34]-GLP-1-(7-37)-peptidyl)-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys-Gly-Gly-Ser-N{Epsilon}[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(19-carboxynonadecanoylamino)hexanoyl]amino]hexanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]Lys

Synthesis method: SPPS_P; SC_L; CP_M2

UPLC02: Rt=8.6 min

LCMS01: Rt=2.2 min; m/4=1716; m/5=1373

Pharmacological Methods Example 29 In Vitro Potency

The purpose of this example is to test the activity, or potency, of theGLP-1 derivatives in vitro. The in vitro potency is the measure of humanGLP-1 receptor activation in a whole cell assay.

The potencies of the GLP-1 derivatives of Examples 1-28 were determinedas described below. Semaglutide was included for comparison.

Principle

In vitro potency was determined by measuring the response of the humanGLP-1 receptor in a reporter gene assay. The assay was performed in astably transfected BHK cell line that expresses the human GLP-1 receptorand contains the DNA for the cAMP response element (CRE) coupled to apromoter and the gene for firefly luciferase (CRE luciferase). When thehuman GLP-1 receptor is activated it results in the production of cAMP,which in turn results in the luciferase protein being expressed. Whenassay incubation is completed the luciferase substrate (luciferin) isadded and the enzyme converts luciferin to oxyluciferin to producebioluminescence. The luminescence is measured as the readout for theassay.

Cell Culture and Preparation

The cells used in this assay (clone FCW467-12A/KZ10-1) were BHK cellswith BHKTS13 as a parent cell line. The cells were derived from a clone(FCW467-12A) that expresses the human GLP-1 receptor and wereestablished by further transfection with CRE luciferase to obtain thecurrent clone.

The cells were cultured at 5% CO₂ in Cell Culture Medium. They werealiquoted and stored in liquid nitrogen. Before each assay an aliquot istaken up and washed twice in PBS before being suspended at the desiredconcentration in the assay specific buffer. For 96-well plates thesuspension was made to give a final concentration of 5×10³ cells/well.

Materials

The following chemicals were used in the assay: Pluronic F-68 (10%)(Gibco 2404), human serum albumin (HSA) (Sigma A9511), ovalbumin (SigmaA5503), DMEM w/o phenol red (Gibco 11880-028), 1 M Hepes (Gibco 15630),Glutamax 100x (Gibco 35050) and steadylite plus (PerkinElmer 6016757).

Buffers

Cell Culture Medium consisted of DMEM medium with 10% FBS (Fetal BovineSerum; Invitrogen 16140-071), 1 mg/ml G418 (Invitrogen 15140-122), 240nM MTX (methotrexate; Sigma M9929) and 1% pen/strep(penicillin/streptomycin; Invitrogen 15140-122).

Assay Medium consisted of DMEM w/o phenol red, 10 mM Hepes and 1×Glutamax. The Assay Buffer consisted of 2% ovalbumin and 0.2% PluronicF-68 in Assay Medium.

Procedure

1) Cell stocks were thawed in a 37° C. water bath.2) Cells were washed three times in PBS.3) The cells were counted and adjusted to 5×10³ cells/50 μl (1×10⁵cells/ml) in Assay Medium. A 50 μl aliquot of cells was transferred toeach well in the assay plate.4) Stocks of the test compounds and reference compounds were diluted toa concentration of 0.2 μM in Assay Buffer. Compounds were diluted10-fold to give the following concentrations: 2×10⁻⁷ M, 2×10⁻⁵ M; 2×10⁻⁹M, 2×10⁻¹⁰ M, 2×10⁻¹¹ M, 2×10⁻¹² M, 2×10⁻¹³ M, and 2×10⁻¹⁴ M.5) A 50 μl aliquot of compound or blank was transferred from thedilution plate to the assay plate. Compounds were tested at thefollowing final concentrations: 1×10⁻⁷ M, 1×10⁻⁸ M; 1×10⁻⁹ M, 1×10⁻¹⁰ M,1×10⁻¹¹ M, 1×10⁻¹² M, 1×10⁻¹³ M, and 1×10⁻¹⁴ M.6) The assay plate was incubated for 3 h in a 5% CO₂ incubator at 37° C.7) The assay plate was removed from the incubator and allowed to standat room temperature for 15 min.8) A 100 μl aliquot of steadylite plus reagent was added to each well ofthe assay plate (reagent was light sensitive).9) Each assay plate was covered with aluminum foil to protect it fromlight and shaken for 30 min at room temperature.10) Each assay plate was read in a Packard TopCount NXT instrument.

Calculations and Results

The data from the TopCount instrument were transferred to GraphPad Prismsoftware. The software performs a non-linear regression (log(agonist) vsresponse). EC₅₀ values which were calculated by the software andreported in pM are shown in Table 1 below.

A minimum of two replicates was measured for each sample. The reportedvalues are averages of the replicates.

TABLE 1 In vitro potency Compound of Example no. EC₅₀ (pM)  1 55  2 36 3 43  4 74  5 61  6 93  7 381  8 260  9 101 10 27 11 27 12 24 13 24 1422 15 20 16 25 17 12 18 13 19 6.2 20 8.4 21 19 22 10 23 22 24 7.0 25 1026 13 27 4.4 28 3.4 semaglutide 8.3

All compounds have potency data that confirms that they are GLP-1receptor agonists.

Example 30 GLP-1 Receptor Binding

The purpose of this example is to test the receptor binding of the GLP-1derivatives in vitro. The receptor binding is a measure of affinity of aderivative for the human GLP-1 receptor.

Principle

The receptor binding of the GLP-1 derivatives of Examples 1-28 to thehuman GLP-1 receptor was measured in a competitive binding assay. Inthis type of assay a labelled ligand (in this case ¹²⁵I-GLP-1) is boundto the receptor. Each derivative is added in a series of concentrationsto isolated membranes containing the human GLP-1 receptor anddisplacement of the labelled ligand is monitored. The receptor bindingis reported as the concentration at which half of the labelled ligand isdisplaced from the receptor, the IC₅₀ value. Semaglutide was included ascomparative compound. In order to test the binding of the derivatives toalbumin, the assay is performed in a low concentration of serum albumin(max. 0.001% final assay concentration as well as in the presence of aconsiderably higher concentration of serum albumin (2.0% final assayconcentration). An increase of the IC₅₀ value in the presence of serumalbumin indicates an affinity to serum albumin and represents a methodto predict a protracted pharmacokinetic profile of the test substance inanimal models.

Materials

The following chemicals were used in the assay: Human serum albumin(HSA) (Sigma A1653), DMEM w/o phenol red (Gibco 11880-028), Pen/strep(Invitrogen 15140-122), G418 (Invitrogen 10131-027), 1 M Hepes (Gibco15630), EDTA (Invitrogen 15575-038), PBS (Invitrogen 14190-094), fetalcalf serum (Invitrogen 16140-071), EGTA, MgCl₂ (Merck 1.05832.1000),Tween 20 (Amresco 0850C335), SPA particles (wheat germ agglutinin (WGA)SPA beads, Perkin Elmer RPNQ0001), [¹²⁵I]-GLP-1]-(7-36)NH₂ (producedin-house), OptiPlate™-96 (Packard 6005290).

Buffer 1 consisted of 20 mM Na-HEPES plus 10 mM EDTA and pH was adjustedto 7.4. Buffer 2 consisted of 20 mM Na-HEPES plus 0.1 mM EDTA and pH wasadjusted to 7.4. Assay buffer consisted of 50 mM HEPES supplemented with5 mM EGTA, 5 mM MgCl₂, 0.005% Tween 20 and pH was adjusted to 7.4. An 8%albumin stock consisted of HSA dissolved at 8% (w/v) in assay buffer. An0.02% albumin stock consisted of HSA dissolved at 0.02% (w/v) in assaybuffer.

Cell Culture and Membrane Preparation

The cells used in this assay (clone FCW467-12A) were BHK cells withBHKTS13 as a parent cell line. The cells express the human GLP-1receptor.

The cells were grown at 5% CO₂ in DMEM, 10% fetal calf serum, 1%Pen/Strep (Penicillin/Streptomycin) and 1.0 mg/ml of the selectionmarker G418.

To make a membrane preparation the cells were grown to approximately 80%confluence. The cells were washed twice in phosphate-buffered saline andharvested. The cells were pelleted using a brief centrifugation and thecell pellet was kept on ice. The cell pellet was homogenised withULTRA-THURRAX™ dispersing instrument for 20-30 seconds in a suitableamount of buffer 1 (e.g., 10 ml). The homogenate was centrifuged for 15minutes. The pellet was re-suspended (homogenised) in 10 ml buffer 2 andcentrifuged. This step was repeated once more. The resulting pellet wasre-suspended in buffer 2 and the protein concentration was determined.The membranes were aliquoted and stored at minus 80° C.

Procedure

1. For the receptor binding assay in the presence of low HSA (0.005%) 50μl of the assay buffer was added to each well of an assay plate. Assaycontinued with step 3.2. For the receptor binding assay in the presence of high HSA (2%) 50 μlof the 8% albumin stock was added to each well of an assay plate. Assaycontinued with step 3.3. Test compounds were serially diluted to give the followingconcentrations: 8×10⁻⁷ M, 8×10⁻⁸ M, 8×10⁻⁹ M, 8×10⁻¹⁰ M, 8×10⁻¹¹ M,8×10⁻¹² M and 8×10⁻¹³ M. Twenty-five μl were added to appropriate wellsin the assay plate.4. Cell membrane aliquots were thawed and diluted to their workingconcentration. Fifty μl were added to each well in the assay plate.5. WGA SPA beads were suspended in assay buffer at 20 mg/ml. Thesuspension was diluted to 10 mg/ml in assay buffer just prior toaddition to the assay plate. Fifty μl were added to each well in theassay plate.6. The incubation was started by adding 25 μl of 480 pM solution of[¹²⁵I]-GLP-1]-(7-36)NH₂ to each well of the assay plate. A 25 μl aliquotwas reserved for measuring total counts/well.7. The assay plate was incubated for 2 h at 30° C.8. The assay plate was centrifuged for 10 min.9. The assay plate was read in a Packard TopCount NXT instrument.

Calculations

The data from the TopCount instrument were transferred to GraphPad Prismsoftware. The software averaged the values for the replicates andperformed a non-linear regression. IC₅₀ values were calculated by thesoftware and reported in nM.

Results

The following results were obtained:

TABLE 2 GLP-1 receptor binding Low Compound of Example no. HSA IC₅₀ (nM)High HSA IC₅₀ (nM) 1 0.75 275 2 1.4 ≧1000 3 1.2 185 4 0.85 113 5 1.1 1016 1.0 ≧1000 7 2.2 197 8 0.43 383 9 1.6 21 10 1.3 123 11 1.5 116 12 1.4212 13 1.4 160 14 1.5 530 15 1.6 928 16 1.4 602 17 1.8 99 18 2.3 219 192.4 142 20 4.1 270 21 1.3 177 22 0.82 194 23 1.4 201 24 0.67 84 25 0.2238 26 0.88 202 27 0.08 30 28 0.05 30 semaglutide 0.56 324

All compounds showed a very good binding to the GLP-1 receptor in theabsence of albumin, and most compounds also showed a very good bindingin the presence of albumin. The two compounds that had IC₅₀ values 1000exceeded the detection limit of the assay.

Example 31 Pharmacokinetic Study in Minipigs

The purpose of this study is to determine the protraction in vivo of theGLP-1 derivatives after i.v. administration to minipigs, i.e. theprolongation of their time in the body and thereby their time of action.This is done in a pharmacokinetic (PK) study, where the terminalhalf-life of the derivative in question is determined. By terminalhalf-life is meant the time it takes to halve a certain plasmaconcentration in the terminal elimination phase.

The derivatives of Examples 1-5 were dosed with 2 nmol/kg, thederivative of Example 6 was dosed with 5 nmol/kg, and the derivatives ofExamples 7-9 were dosed with 15 nmol/kg. Semaglutide was included forcomparison (1.5 nmol/kg).

Male Göttingen minipigs were obtained from Ellegaard Göttingen Minipigs(Dalmose, Denmark) approximately 7-14 months of age and weighingapproximately 16-35 kg were used in the studies. The minipigs werehoused either individually (pigs with permanent catheters) or in a groupand fed restrictedly once or twice daily with SDS minipig diet (SpecialDiets Services, Essex, UK).

After at least 2 weeks of acclimatisation two permanent central venouscatheters were implanted in vena cava caudalis or cranialis in eachanimal. The animals were allowed 1 week recovery after the surgery, andwere then used for repeated pharmacokinetic studies with a suitablewash-out period between successive GLP-1 derivative dosings.

The GLP-1 derivatives were dissolved in 50 mM sodium phosphate, 70-145mM sodium chloride, 0.05% tween 80, pH 7.4 to a concentration of usuallyfrom 20-60 nmol/ml.

Intravenous injections (the volume corresponding to for example0.050-0.125 ml/kg) of the compounds were given through one catheter orthrough the venflon, and blood was sampled at predefined time points forup till 25 days post dosing (preferably through the other catheter or byvenipuncture). Blood samples (for example 0.8 ml) were collected in EDTAbuffer (8 mM) and then centrifuged at 4° C. and 1942G for 10 minutes.

Plasma was pipetted into Micronic tubes on dry ice, and kept at −20° C.until analysed for plasma concentration of the respective GLP-1 compoundusing LOCI. Individual plasma concentration-time profiles were analyzedby a non-compartmental pharmacokinetic method in Phoenix v. 6.2(Pharsight Inc., Mountain View, Calif., USA), or other relevant softwarefor PK analysis, and the resulting terminal half-lives (harmonic mean)determined.

Results

TABLE 3 Pharmacokinetic study in minipids (i.v.) Compound of Example no.Terminal half-live (h) 1 121 2 110 3 147 4 137 5 131 6 99 7 106 8 137 9167 semaglutide 55

The tested derivatives of the invention have very long terminalhalf-lives (at least twice that of semaglutide).

Example 32 Pharmacodynamic Study in db/db Mice

The purpose of the study is to verify the acute effect of the GLP-1derivatives on blood glucose (BG) and body weight (BW) in a diabeticsetting.

The GLP-1 derivatives of Examples 1-8, and 10 were tested in asingle-dose study in an obese, diabetic mouse model (db/db mice) asdescribed in the following. The derivatives were tested at a dose of 10nmol/kg (Example 10), or 30 nmol/kg (Examples 1-8).

Six db/db mice per compound to be tested (from Taconic, Denmark), fedfrom birth with the diet NIH31 (NIH 31M Rodent Diet, commerciallyavailable from Taconic Farms, Inc., US, see www.taconic.com), wereenrolled for the study at the age of approximately 10 weeks. The micewere given free access to standard chow (e.g. Altromin 1324, Brogaarden,Gentofte, Denmark) and tap water and kept at 24° C. After 1-2 weeks ofacclimatisation, the basal blood glucose was assessed twice on twoconsecutive days (i.e. at 9 am). The mice were allocated to treatmentgroups based on matching blood glucose levels and body weights. The micewere used in experiments with a duration of 120 hours, and were re-usedfor up to 2 times. After the last experiment the mice were euthanised.

The animals were grouped to receive treatment as follows: Vehicle, s.c.,or GLP-1 derivative, s.c., where vehicle was either 50 mM sodiumphosphate, 70 mM sodium chloride, 0.05% polysorbate 80, pH 7.4 (Examples1, 2, 7, and 10); or 50 mM sodium phosphate, 145 mM sodium chloride,0.05% (w/v) tween 80, pH 7.4 (Examples 3-6, and 8).

The GLP-1 derivative was dissolved in the vehicle, to a dosingconcentration of 1.7-17 nmol/ml dependent on the respective dose.Animals were dosed once, at the start of the experiment, s.c. with adose-volume of 6 ml/kg (i.e. 300 μl per 50 g mouse).

On the day of dosing, blood glucose was assessed at time—½ h (8.30 am),the mice were weighed after this. The GLP-1 derivative was dosed atapproximately 9 am (time 0). On the day of dosing, blood glucose wasassessed at times 1, 2, 4 and 8 h (10 am, 11 am, 1 pm and 5 pm) afterdosing.

On the following days, the blood glucose was assessed at time 24 h, 48h, 72 h, and 96 h. On each day, the mice were weighed following bloodglucose sampling.

The mice were weighed individually on a digital weighing scale.

Samples for the measurement of blood glucose were obtained from the tailtip capillary of conscious mice. Blood, 10 μl, was collected intoheparinised capillaries and transferred to 500 μl glucose buffer (EKFsystem solution, Eppendorf, Germany). The glucose concentration wasmeasured using the glucose oxidase method (glucose analyser Biosen 5040,EKF Diagnostic, GmbH, Barleben, Germany). The samples were kept at roomtemperature for up to 1 h until analysis. If analysis had to bepostponed, samples were kept at 4° C. for a maximum of 24 h.

The data are presented as percent change in blood glucose or body weightmeasured at the 48 h and the 96 h time points. For example, the percentchange in blood glucose level at 48 h for each individual is calculatedas follows: [[(blood glucose level at 48 h)−(basal blood glucoselevel)]/(basal blood glucose level)]×100%], where basal blood glucoselevel refers to the level before the administration of any treatment—andvice versa for the body weight change. A negative value refers to a %reduction.

The following results were obtained (averages of all individualdeterminations corresponding to the respective treatment):

TABLE 4 Effect on blood glucose and body weight in db/db mice % changein % change in Compound of blood glucose body weight Example no. 48 h 96h 48 h 96 h 1 −61 −21 −6 −3 2 −37 −31 −4 −2 3 −58 −22 −5 −3 4 −30 −18 −4−3 5 −28 −33 −4 −3 6 −30 −21 −3 −4 7 −49 −17 −4 −1 8 −39 −31 −4 −4 10−17 −3 −3 −3

All derivatives tested showed effect in vivo by decreasing BG as well asBW after 48 h as well as after 96 h.

Example 33 Pharmacodynamic Study in LYD Pig

The purpose of this experiment is to investigate the effect of GLP-1derivatives on food intake in pigs. This is done in a pharmacodynamic(PD) study as described below, in which food intake is measured from 1to 4 days after administration of a single dose of the GLP-1 derivative,as compared to a vehicle-treated control group.

Female Landrace Yorkshire Duroc (LYD) pigs, approximately 3 months ofage, weighing approximately 30-35 kg are used (n=3-4 per group). Theanimals are housed in a group for approximately 1 week duringacclimatisation to the animal facilities. During the experimental periodthe animals are placed in individual pens at least 2 days before dosingand during the entire experiment for measurement of individual foodintake. The animals are fed ad libitum with pig food (Svinefoder, DanishTop, or HRC Sow and Weaner Diet) at all times both during theacclimatisation and the experimental period. Food intake is monitoredeither on line by logging the weight of food every 15 minutes, ormanually. The weight of food is recorded daily for each animal (24 hperiods) from day −2 to day 6 (120 hour) after dose, administrationinclusive.

The GLP-1 derivatives are first dissolved in a phosphate buffer (50 mMphosphate, 0.05% tween 80, pH 8; or 50 mM phosphate, 145 mM sodiumchloride, 0.05% tween 80, pH 7.4) at the desired concentration (such as12, 40, 120, 400 or 1200 nmol/ml corresponding to doses of 10, 15, or 30nmol/kg). The phosphate buffer serves as vehicle. Animals are dosed witha single subcutaneous dose of the GLP-1 derivative or vehicle (usualdose volume 0.025 ml/kg) on the morning of day 1, and food intake ismeasured for 1-4 days after dosing. On the last day of each study, 1-4days after dosing, a blood sample for measurement of plasma exposure ofthe GLP-1 derivative is taken from the jugular/anterior vena cava. Theanimals are re-used for three experiments. Plasma content of the GLP-1derivatives is analysed using LOCI.

Food intake is calculated as mean 24 h food intake in 24 h intervals(0-24 h, 24-48 h, 48-72 h, and 72-96 h) and may, e.g., be indicated aspercentage of the food intake of the vehicle group in the same timeinterval.

Statistical comparisons of the food intake in the 24 hour intervals inthe vehicle vs. GLP-1 derivative group are done using two-way-ANOVArepeated measures, followed by Bonferroni post-test.

While certain features of the invention have been illustrated anddescribed herein, many modifications, substitutions, changes, andequivalents will now occur to those of ordinary skill in the art. It is,therefore, to be understood that the appended claims are intended tocover all such modifications and changes as fall within the true spiritof the invention.

1. A derivative of a GLP-1 analogue, wherein the GLP-1 analoguecomprises a sequence of Formula I: Formula I:Xaa₇-Xaa₈-Glu-Gly-Thr-Xaa₁₂-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Xaa₃₁-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂,

wherein Xaa₇ is L-histidine,(S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid, D-histidine,desamino-histidine, homohistidine, N^(α)-acetyl-histidine,N^(α)-formyl-histidine, N^(α)-methyl-histidine, 3-pyridylalanine,2-pyridylalanine, or 4-pyridylalanine; Xaa₈ is Ala, Gly, Ser, Aib,(1-aminocyclopropyl) carboxylic acid, or (1-aminocyclobutyl) carboxylicacid; Xaa₁₂ is Phe or Leu; Xaa₁₆ is Val or Leu; Xaa₁₈ is Ser, Arg, Lys,Val, or Leu; Xaa₁₉ is Tyr or Gln; Xaa₂₀ is Leu or Met; Xaa₂₂ is Gly orGlu; Xaa₂₃ is Gln, Glu, Lys, or Arg; Xaa₂₅ is Ala or Val; Xaa₂₆ is Argor Lys; Xaa₂₇ is Glu, Lys, or Leu; Xaa₃₀ is Ala, Glu, or Arg; Xaa₃₁ isTrp, Lys, or His; Xaa₃₃ is Val, Lys, or Arg; Xaa₃₄ is Lys, Arg, His,Asn, or Gln; Xaa₃₅ is Gly or Ala; Xaa₃₆ is Lys; Xaa₃₇ is Gly or Pro;Xaa₃₈ is Ser, Gly, Ala, Glu, Pro, or Lys; Xaa₃₉ is Ser, Gly, Ala, Glu,or Pro; Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₁ is Ser, Gly, Ala,Glu, or Pro; and Xaa₄₂ is Lys; wherein Lys at Xaa₄₂ is a first Kresidue, and Lys at Xaa₃₆ is a second K residue; which derivativecomprises a first and a second protracting moiety connected to saidfirst and second K residue, respectively, wherein the first and thesecond protracting moiety is selected from Chem. 1, Chem. 1a, and Chem.1b:HOOC—(CH₂)₁₈—CO—*,  Chem. 1:HOOC—(CH₂)₁₇—CO—*, and  Chem. 1a:HOOC—(CH₂)₂₀—CO—*;  Chem. 1b: or a pharmaceutically acceptable salt,amide, or ester thereof.
 2. The derivative of claim 1, wherein Xaa₈ isAib.
 3. The derivative of claim 2, wherein Xaa₂₂ is Glu.
 4. Thederivative of claim 3, wherein Lys at Xaa₄₂ and Lys at Xaa₃₆ are theonly Lys residues.
 5. The derivative of claim 4, wherein Xaa₃₄ is Arg.6. The derivative of claim 5, wherein the GLP-1 analogue has a maximumof 12 amino acid changes when compared with GLP-1(7-37) (SEQ ID NO: 1).7. The derivative of claim 6, wherein each of the first and the secondprotracting moiety is attached to the first and the second K residue,respectively, via a first and a second linker, respectively.
 8. Thederivative of claim 7, wherein each of the first and the second linkercomprises at least one linker element selected from the following:

wherein k is an integer in the range of 1-5, and n is an integer in therange of 1-5;

wherein q is an integer in the range of 0-5, and w is an integer in therange of 0-5, with the provisos that when w is 0 q is an integer in therange of 1-5, and when q is 0 w is an integer in the range of 1-5;

wherein y is 1 or 2, z is 1 or 2, p is 0 or 1, and X designates a carbonatom or an oxygen atom; and


9. The derivative of claim 1, wherein in Formula I Xaa₇ is L-histidine,(S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid, D-histidine,desamino-histidine, N^(α)-acetyl-histidine, N^(α)-formyl-histidine,N^(α)-methyl-histidine; Xaa₈ is Ala, Gly, Ser, Aib, (1-aminocyclopropyl)carboxylic acid, or (1-aminocyclobutyl) carboxylic acid; Xaa₁₂ is Phe;Xaa₁₆ is Val or Leu; Xaa₁₈ is Ser, Arg, or Lys; Xaa₁₉ is Tyr or Gln;Xaa₂₀ is Leu or Met; Xaa₂₂ is Gly or Glu; Xaa₂₃ is Gln, Glu, Lys, orArg; Xaa₂₅ is Ala or Val; Xaa₂₆ is Arg or Lys; Xaa₂₇ is Glu, Lys, orLeu; Xaa₃₀ is Ala or Glu; Xaa₃₁ is Trp, Lys, or His; Xaa₃₃ is Val, Lys,or Arg; Xaa₃₄ is Lys, Arg, or Asn; Xaa₃₅ is Gly; Xaa₃₆ is Lys; Xaa₃₇ isGly or Pro; Xaa₃₈ is Gly, Ala, Glu, Pro, or Lys; Xaa₃₉ is Ser, Gly, Ala,Glu, or Pro; Xaa₄₀ is Ser, Gly, Ala, Glu, or Pro; Xaa₄₁ is Ser, Gly,Ala, Glu, or Pro; and Xaa₄₂ is Lys.
 10. The derivative of claim 9,wherein Xaa₁₈ is Ser, or Arg; Xaa₂₃ is Gln, Glu, or Arg; Xaa₂₅ is Ala orVal; Xaa₂₆ is Arg: Xaa₂₇ is Glu, or Leu; Xaa₃₁ is Trp, or His; Xaa₃₃ isVal, or Arg; and Xaa₃₄ is Arg, or Asn.
 11. The derivative of claim 10,wherein in Formula I: Xaa₈ is Aib and Xaa₂₂ is Glu.
 12. The derivativeof claim 11, wherein the GLP-1 like peptide has a maximum of 12 aminoacid changes when compared with GLP-1(7-37) (SEQ ID NO: 1).
 13. Thederivative of claim 12, wherein each of the first and the secondprotracting moiety is attached to the first and the second K residue,respectively, via a first and a second linker, respectively.
 14. Thederivative of claim 13, wherein each of the first and the second linkercomprises at least one linker element selected from the following:

wherein k is an integer in the range of 1-5, and n is an integer in therange of 1-5;

wherein q is an integer in the range of 0-5, and w is an integer in therange of 0-5, with the provisos that when w is 0 q is an integer in therange of 1-5, and when q is 0 w is an integer in the range of 1-5;

wherein y is 1 or 2, z is 1 or 2, p is 0 or 1, and X designates a carbonatom or an oxygen atom; and


15. The derivative of claim 14, wherein in Formula I Xaa₇ isL-histidine; Xaa₁₂ is Phe; Xaa₁₆ is Val; Xaa₁₈ is Ser; Xaa₁₉ is Tyr;Xaa₂₀ is Leu; Xaa₂₃ is Gln; Xaa₂₅ is Ala; Xaa₂₇ is Glu; Xaa₃₀ is Ala;Xaa₃₁ is Trp; Xaa₃₃ is Val; Xaa₃₄ is Arg; and Xaa₃₇ is Gly.
 16. Thederivative of claim 15, wherein in Formula I Xaa₃₈ is Gly, Ala, Glu, orPro; Xaa₃₉ is Gly, Ala or Glu; Xaa₄₀ is Ser, Gly, or Pro; and Xaa₄₁ isSer, Ala, Glu, or Pro.
 17. A GLP-1 derivative selected from thefollowing:

where the amino acid sequence is that of SEQ ID NO:6,

where the amino acid sequence is that of SEQ ID NO:9,

where the amino acid sequence is that of SEQ ID NO: 11, and

where the amino acid sequence is that of SEQ ID NO: 10, or apharmaceutically acceptable salt, amide, or ester thereof.
 18. Apharmaceutical composition comprising a derivative according to claim 1and a pharmaceutically acceptable excipient.
 19. A pharmaceuticalcomposition comprising a derivative according to claim 17 and apharmaceutically acceptable excipient.
 20. A method for treating asubject having hyperglycemia, type 2 diabetes, impaired glucosetolerance, type 1 diabetes, non-insulin dependent diabetes, MODY(maturity onset diabetes of the young), and/or gestational diabetes,said method comprising administering to a subject in need of suchtreatment a therapeutically effective amount of the pharmaceuticalcomposition of claim
 18. 21. A method for treating obesity in a subject,said method comprising administering to a subject in need of suchtreatment a therapeutically effective amount of the pharmaceuticalcomposition of claim 18.